Stockwinners Market Radar for September 07, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:37 EDT India Globalization Capital completes phase 1 trial of IGC-AD1 in AD patients - India Globalization Capital "announces the completion of its Phase 1 clinical trial on IGC's cannabis-based investigational new drug, IGC-AD1, for patients suffering from Alzheimer's disease. As previously disclosed, IGC submitted IGC-AD1 to the FDA under Section 505(i) of the Federal Food, Drug, and Cosmetic Act. IGC received approval to proceed with the Phase 1 trial from the FDA on July 30, 2020. The primary end point of this Phase 1 trial was safety and tolerability. Based on this study, and subject to FDA concurrence, generally, the cannabis-based investigational drug IGC-AD1 was safe and well-tolerated by the Alzheimer's trial participants. The trial was conducted on 12 participants suffering from Alzheimer's disease. The participants represent a frail geriatric population with multiple comorbidities and mild to moderate Alzheimer's disease."

19:33 EDT Huntsman says Ida caused no significant damage to Geismar facility - Huntsman "disclosed that Hurricane Ida caused no significant damage to its Geismar, Louisiana manufacturing facility. The Geismar facility manufactures products for Huntsman's Polyurethanes and Performance Products divisions and all units were shutdown orderly and safely before Hurricane Ida made landfall. Site personnel are currently preparing the production units for restart. The precise timing of the restart of each unit is dependent on the availability of utilities and the ability of other third-party suppliers to restart their respective operations. Currently, the company's best estimate is that production comes back online slowly this coming weekend with an increase in rates next week. Under this timeline, the Company currently anticipates that the estimated impact from Hurricane Ida to third quarter 2021 EBITDA will be offset by strength in the broader Performance Products division and the European and Asian MDI markets."

19:02 EDT Microsoft acquires Clipchamp, terms not disclosed - Microsoft said in a blog post that it is acquiring Clipchamp, an in-browser video creation and editing experience. "Clipchamp's template-driven, task-focused user experience gives everyone the confidence that they can create," Microsoft said. "Its rich library of filters, styles, transitions, and stock media combined with the power of a multi-track audio and video compositing editor gives everyone the fine control they need, and artistic help if they need it, to create exactly what they want, quickly and with confidence. Once you finish your story, Clipchamp helps you share it since it's built for social media, offering output styles and aspect ratios for all the popular social networks. It lets you tell your story your way. Small business owners, marketers, influencers, students, educators, families, and information workers of all types need the capability to make great videos with minimal effort. Whether it's a 10-second social media ad, a 2-minute pitch for a product, or a 20-minute instructional video, Clipchamp and Microsoft will provide the tools and experience you need." Reference Link

18:19 EDT Volkswagen planning EUR300M venture capital fund for decarbonization projects - Volkswagen chairman Herbert Diess said in a LinkedIn post that the car maker is planning a venture capital fund with an initial volume of EUR300M that it will invest in a number of decarbonization projects and innovative start-ups. "Climate change will be the greatest challenge for humanity in the coming decades," Diess said. "With virtually unlimited burning of coal, oil and gas, climate change is steadily accelerating. More and more people are realizing how dramatic the situation is and want to take action." Reference Link

17:33 EDT Oscar Health co-founder buys $8.77M in common stock - In a regulatory filing, Oscar Health disclosed that its co-founder Joshua Kushner bought 485.5K shares of common stock on September 2nd in a total transaction size of $8.77M.

17:31 EDT Wynn Resorts - Genius Sports Limited (GENI) announced an expansion of its existing supplier agreement with WynnBET, the premier sports betting app from Wynn Resorts (WYNN) to provide NFL official sportsbook data, content and fan engagement solutions. This new partnership builds on Genius Sports' long-term relationship with WynnBET, which provides trading solutions and official data-driven content from the Company's exclusive sports partnerships with the English Premier League, Liga MX, Argentine and Colombian soccer. WynnBET is licensed to operate across seven U.S. States in Arizona, Colorado, Indiana, Michigan, New Jersey, Tennessee and Virginia.

17:16 EDT Midland States announces $25M expansion of stock buyback program - Midland States announced that its board has approved modifications to the company's previously announced stock repurchase program, which increase the aggregate repurchase authority to $75M from $50M, and extend the expiration date of the program to December 31, 2022. As of August 31, 2021, after giving effect to the modifications, there was approximately $26.3 million remaining under the stock repurchase program authorization.

17:08 EDT Casey's General Stores sees FY22 SSS for fuel, inside sales up mid-single digits - The Company "is maintaining the previously disclosed fiscal 2022 outlook, with one modification. The tax rate is now expected to be approximately 24.0% - 26.0% for the year. The remainder of the key metrics are unchanged. The Company expects same-store fuel and inside sales to increase by mid-single digit percentages. Total operating expenses are expected to increase by mid-teen percentages, driven primarily by adding approximately 200 units during fiscal 2022, as well as expenses related to adding back operating hours to the stores and expected wage pressures. Depreciation and amortization is expected to be approximately $300M, interest expense is expected to be approximately $50M."

17:00 EDT Ascendis Pharma submits IND application to initiate TransCon IL-2 program - Ascendis Pharma announced the submission of an investigational new drug application with the U.S. Food & Drug Administration to initiate IL betaeliegammae Trial, a phase 1/2 clinical trial to evaluate TransCon IL-2 beta/gamma in patients with advanced cancer. TransCon IL-2 beta/gamma is an investigational long-acting prodrug designed to improve cancer immunotherapy by sustained exposure to an IL-2 variant that selectively activates the IL-2Rbeta/gamma, with minimal binding to IL-2Ralpha. "This IND submission for our second clinical stage oncology product candidate represents another major milestone for Ascendis. Our understanding of the biology has guided us in designing a novel parent drug, which we have combined with our clinically validated TransCon platform. We believe this combination has the potential to overcome the known shortcomings of current IL-2 compounds, such as low potency, short half-life and high Cmax. By solving the different elements related to efficacy and safety independently, we believe it will be possible to realize the full potential of the IL-2 pathway and create a potentially best-in-class cancer immunotherapy product," said Kennett Sprogoe, Ph.D., Ascendis Pharma's Head of Innovation and Research.

16:51 EDT Stratus Properties acquires land to develop Block 150 in Austin - Stratus Properties announced its plans for Block 150, a proposed high-rise rental project in downtown Austin, Texas. The site at 12th and San Antonio is located just a few blocks west of the Texas State Capitol in Austin. Based on preliminary plans, Block 150 would be developed as a 400-foot tower, consisting of approximately 420,000 gross square feet with 300 Class A luxury multi-family units for lease and ground-level retail. The project includes the AO Watson house, which will be renovated and expanded to offer amenities that may include a restaurant, pool and garden, while preserving the property's historic and architectural features. Stratus' subsidiary closed the land purchase on September 1 and Stratus expects to finalize development plans over the next 12 to 18 months. The project is owned by Stratus Block 150, L.P., a Texas limited partnership. Financing for the land purchase and predevelopment costs is in place and includes a land acquisition loan to the limited partnership in the amount of $14M, guaranteed by Stratus. The remaining land acquisition and predevelopment costs will be funded by approximately $21M in equity contributed to the limited partnership by Stratus and private equity investors. Stratus will receive 25% of the limited partnership's equity, in exchange for development costs to date and cash, and will manage the project. Upcoming key milestones for the project include completing design and engineering, securing final site development and building permits, obtaining downtown density bonus approvals, and raising the balance of the development capital, which Stratus projects could take between 12 to 18 months. Subject to market conditions, obtaining financing for the balance of the development capital, board approval, and necessary project approvals, entitlements and permits, construction on Block 150 is expected to begin in early 2023 with anticipated completion in mid-2025.

16:35 EDT Myomo announces granting of patents in China, Hong Kong - Myomo announced the granting of patents in China and Hong Kong covering the company's most advanced products. Patent number ZL201680032072 was issued in China and patent number 1251447B was issued in Hong Kong. The patents are titled "Powered Orthotic Device and Method of Using Same," which cover a powered orthotic device that supports movement of a user's arm about the elbow and a user's fingers and thumb to support grasping. These newly issued patents are in force through June 2036. These patents are expected to be licensed to a newly formed company in China, Jiangxi Myomo Medical Assistive Appliance Co., Ltd., which was established on August 12, 2021, pursuant to an Equity Joint Venture Contract entered into between the Company and Beijing Ryzur Medical Investment Co., Ltd. in January 2021. A Technology License Agreement between the Company and the JV Company is expected to be entered into once certain operational and financial milestones by Ryzur and the JV Company are met. David Ren, founder and President of Ryzur, commented "We are looking forward to partnering with Myomo to bring this advanced technology to hospitals and patients in China. Now that the JV company is established, our next steps are to complete the funding, introduce the MyoPro to distributors and hospitals and set up the operations for launch of the products in the large China market."

16:33 EDT Alector announces top management changes - Alector announced that Shehnaaz Suliman, and Robert Paul will be stepping down from their respective roles as President and COO and Chief Medical Officer. Each will continue to serve for a transition period and plan to remain available as advisors until the end of 2021. Sam Jackson, Senior Vice President, Clinical Sciences, will assume the role of interim Chief Medical Officer. Jackson is an established leader with more than 15 years of experience leading clinical development functions. He joined Alector in 2020 and among his primary responsibilities is the development of AL001, which is currently in Phase 3 clinical testing for the treatment of frontotemporal dementia. Suliman joined Alector in 2019 and provided strategic and operational leadership while overseeing the company's early development, portfolio, business development, finance, investor relations, legal and administrative functions. Robert Paul joined Alector in 2016 and has been responsible for advancing all four of Alector's immuno-neurology programs into the clinic and laying the foundation for the company's overarching development strategy. Sam Jackson, joined Alector as the Senior Vice President of Clinical Development in 2020 bringing more than 15 years of industry experience leading clinical development for novel neurologic, immunologic and ophthalmic programs.

16:31 EDT NESR, Cactus announce collaboration in the Middle East - National Energy Services Reunited Corp. (NESR) and Cactus (WHD) announced that they have entered into an agreement to provide and deploy Cactus frac rental equipment in the Middle East, as well as other initiatives in the key markets. Scott Bender, President and CEO of Cactus stated, "The differentiated nature of Cactus' products and service execution has enabled us to significantly expand our presence across U.S. unconventional basins over the last several years. Through this new agreement with NESR, we are extending this model to customers in the MENA region. We have highlighted the Middle East as an area of potential future growth and we are pleased to have officially deployed assets and personnel in the region, working together with NESR. We are excited about the expansion of unconventional oil & gas development activities in the Middle East and hope to leverage NESR's extensive footprint and excellent customer relationships to grow the business."

16:30 EDT Asur reports August 2021 passenger traffic down 4.3% vs August 2019 - Asur announced that total passenger traffic for August 2021 reached a total of 4.6 million passengers, 4.3% below the levels reported in August 2019, reflecting a continued recovery in travel demand in general and the rollout of vaccination campaigns in the US and gradual advances in Mexico, despite restrictions and requirements in certain countries of the world to contain the spread of the virus. When compared to pre-pandemic levels of August 2019, passenger traffic declined 8.4% in Mexico and 7.6% in Colombia, while traffic in Puerto Rico increased 14.8%. This announcement reflects comparisons between August 1 through August 31, 2021, from August 1 through August 31, 2020 and August 1 through August 31, 2019. Transit and general aviation passengers are excluded for Mexico and Colombia.

16:25 EDT MacroGenics trading halted, news pending

16:21 EDT Mercury Systems appoints Thomas Huber as chief transformation officer - Mercury Systems announced that Thomas Huber has joined the company as executive vice president and chief transformation officer, effective immediately. Reporting to Mark Aslett, Mercury's president and chief executive officer, Huber will lead the company's 1MPACT strategic value creation initiative announced in its Q4 earnings release. Huber brings to Mercury 20 years of global experience in industry and management consulting. Prior to joining Mercury, Huber was managing director and partner at the Boston Consulting Group, serving as a member of their transformation and operations practice areas.

16:17 EDT Equifax completes acquisition of Teletrack - Equifax announced that it has completed the acquisition of Teletrack, a U.S. leader in alternative credit data, from CoreLogic. The definitive agreement to acquire Teletrack was announced on July 27. The combination of Teletrack with the Equifax DataX business will create a leading U.S. specialty consumer reporting agency, with data on more than 80 million thin-file, unbanked, underbanked and credit rebuilding consumers that can help to expand access to credit through alternative data insights. The transaction is not anticipated to have a material impact on 2021 Equifax financial results. Teletrack is now part of the USIS business unit at Equifax.

16:16 EDT MVB Bank, NYDIG partner to offer white label Bitcoin and banking platform - MVB Bank, Inc., a wholly-owned subsidiary of MVB Financial Corp., and Victor Technologies, Inc., a wholly-owned subsidiary of MVB Edge Ventures, Inc., announced a partnership with NYDIG, a technology and financial services firm dedicated to Bitcoin, to integrate Bitcoin into MVB's Banking-as-a-Service solutions. This partnership will allow MVB's Fintech clients to offer Bitcoin-related products - all powered by NYDIG's secure, regulated, full-stack platform - alongside the banking products MVB enables today. "On today's rapidly changing financial frontier, we are proud to partner with a firm like NYDIG," said Larry F. Mazza, CEO and President, MVB Financial. "NYDIG has a vision to make Bitcoin more accessible. Adding Bitcoin functionality to MVB's already industry-leading Banking-as-a-Service solutions will propel that vision into reality and help our clients compete."

16:12 EDT UiPath raises FY22 ARR view to $876M-$881M from $850M-$855M

16:10 EDT Sonoco teams with robotics firm AMP Robotics for rigid paperboard can recycling - Sonoco announced it has partnered with AMP Robotics, a pioneer in AI, robotics and infrastructure for the waste and recycling industry, to create a new material category within AMP's neural network specific to rigid paperboard cans. The U.S. partnership will result in increased recycling rates for the spiral wound paper canister with steel bottom produced by Sonoco and other manufacturers. The use of recycled steel has a 45% lower environmental impact than producing the equivalent amount from virgin material, reducing the need to mine for virgin iron ore. Additionally, when compared to landfilling, recycling the paper container with steel bottom through the steel or other streams has a greater than 40% lower environmental impact than landfilling. Any materials recovery facility with anAMPCortex intelligent robotics system can now accurately and efficiently sort Sonoco's paper can to the desired stream.

16:01 EDT Central Valley Community names James Kim as new CEO - The Board of Directors of Central Valley Community announced that Executive Vice President and COO James J. Kim has been promoted to President and CEO of the company and bank effective November 1, 2021. Kim succeeds President and CEO James Ford who previously notified the Board in March 2021 of his intention to retire from the company and bank following the transition to new leadership. Daniel J. Doyle will continue as chairman of the company and bank.

15:52 EDT Microsoft introduces personalized news feed Microsoft Start - Liat Ben-Zur, Corporate Vice President of Microsoft said on a blog entry, earlier, in part: "It should be simple to catch up on the things we care about. Yet, I find it can be overwhelming. I'm inundated by news, information and on-going alerts across online sources, media channels and devices. It turns out, I'm not alone... I want content on a range of topics all in a single destination. I want access to this on my PC and my phone...To address this need, we're introducing Microsoft Start. This personalized news feed and collection of informational content provides news from premium publishers, timely updates tailored to your interests, and is available when and where you want it...Microsoft Start builds on Microsoft's legacy with online and mobile consumer services like MSN and Microsoft News. MSN has been bringing customers news and online content for over 25 years and will remain available. We will continue to build on our commitment to news and our publisher ecosystem, adding value for both partners and customers alike....Microsoft Start on the PC - I can now start my day on the PC with information on my news and interests only a click away. I can go directly to the Microsoft Start website from Microsoft Edge or Chrome. Moreover, there are even more convenient ways for me to access the experience from Windows and Edge: News and interests on the Windows 10 taskbar is the fastest way for me to stay up to date on my Windows 10 PC. I can open my feed by clicking the weather icon in my taskbar. Then when I click on any content, I land in Microsoft Start...Microsoft Start on the PC - I can now start my day on the PC with information on my news and interests only a click away. I can go directly to the Microsoft Start website from Microsoft Edge or Chrome. Moreover, there are even more convenient ways for me to access the experience from Windows and Edge: News and interests on the Windows 10 taskbar is the fastest way for me to stay up to date on my Windows 10 PC. I can open my feed by clicking the weather icon in my taskbar. Then when I click on any content, I land in Microsoft Start." Reference Link

15:03 EDT Ford hires Apple's Field as Chief Advanced Technology, Embedded Systems Officer - Ford Motor Company (F) named Doug Field as the company's chief advanced technology and embedded systems officer as it said it "continues to advance its Ford+ growth plan." Field joins Ford from Apple (AAPL), where he served as VP, Special Projects. Before that, he was senior vice president, Engineering, at Tesla (TSLA). His appointment to Ford is effective today, and he reports to Ford President and CEO Jim Farley. "Doug is one of the world's most respected engineering and product design leaders and has been a driving force behind breakthrough products across auto, tech and mobility, including at Apple, Tesla and Segway. His talent and commitment to innovation that improves customers' lives will be invaluable as we build out our Ford+ plan to deliver awesome products, always-on customer relationships and ever-improving user experiences. We are thrilled Doug chose to join Ford and help write the next amazing chapter of this great company," Farley said. Field will partner closely with Hau Thai-Tang, Ford's chief product platform and operations officer, to create the next generation of Ford's connected products and experiences. Thai-Tang will continue to oversee Product Development, Purchasing, Design, Research & Advanced Engineering, EPLM / D-Ford, Advanced Manufacturing and Ford Ion Park, the company stated.

14:28 EDT NeuroOne Medical Technologies receives FDA clearance for Evo sEEG Electrode - NeuroOne Medical Technologies Corporation announced that it has received U.S. Food and Drug Administration 510(k) clearance to market its Evo sEEG Electrode technology for temporary use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain. "This represents yet another critical milestone met by the Company as we continue to execute our strategy. The next steps for the Company are to expand the sEEG labeling for longer term use, which we believe will be a key part of our commercialization strategy for the Evo sEEG electrode, and complete development of an sEEG ablation electrode/probe for ablation of brain tissue and permanently implanted stimulation electrodes for patients with chronic applications such as epilepsy, Parkinson's disease and chronic back pain," said Dave Rosa, CEO of NeuroOne. As previously reported, the company expects to be launch ready by the end of calendar year 2021, pending additional regulatory clearance of sEEG labeling for longer term use.

14:01 EDT RingCentral reports resignation of Chief Strategy Officer - In a regulatory filing after the close on Friday night, RingCentral disclosed that on August 30, 2021, Praful Shah notified the company of his resignation from his position as the Company's Chief Strategy Officer effective as of September 14, 2021. "Shah's resignation did not involve any disagreement on any matter related to the Company's operations, policies, or practices... In connection with his resignation, on September 2, 2021, Mr. Shah entered into a non-competition agreement effective as of the separation date. Pursuant to the Agreement, Mr. Shah has agreed to not, without the prior written consent of the company, engage in certain competitive business activities towards the company or solicit certain other individuals to participate in such activities from the period commencing on the separation date until August 20, 2022," the filing stated.

13:58 EDT Intel's Mobileye unveils 6-passenger, electric AV for driverless ride hailing - Mobileye, an Intel company, unveiled the 6-passenger, road-ready electric autonomous vehicle that will be used for commercial driverless ride-hailing services in Tel Aviv and Munich starting in 2022. Equipped with the Mobileye Drive self-driving system featuring 8 EyeQ5 SoCs in the AVKIT58, the all-electric Mobileye AVs will operate under the MoovitAV service branding, the company said.

13:07 EDT Anheuser-Busch announces new U .S. commercial structure - Anheuser-Busch announced enhancements to its U.S. commercial leadership team to further support the company's consumer-first commercial strategy. "Over the last four years, we have developed and implemented a clear and consistent consumer-first strategy that has resulted in strong momentum for our U.S. business," said Brendan Whitworth, CEO, Anheuser-Busch. "The new commercial structure we are announcing today, along with key leadership changes, will make us better partners to our wholesalers and retailers, ultimately accelerating our momentum in the U.S." First, Kyle Norrington, currently President of Labatt in Canada, will assume a new role as U.S. Chief Commercial Officer, overseeing Sales and Marketing in the U.S. Second, Simon Wuestenberg, currently President of Anheuser-Busch's wholly owned distributor business unit AB ONE, is appointed U.S. Chief Sales Officer. Marcel Marcondes, currently U.S. Chief Marketing Officer, is transitioning to a new role within AB InBev that will be announced at a later date.

12:08 EDT Digital Ally healthcare unit acquires medical billing company for $2.92M - Digital Ally announces that its healthcare subsidiary, Nobility Healthcare, has acquired a second medical billing company located in the Midwest with annual revenues of approximately $3M. The company provides revenue cycle management services for over 40 clients who are located chiefly in the Midwest, the company said. The purchase price was $2.92M, with approximately 77% paid in cash at the closing and the balance through an earn-out promissory note bearing interest at 3% payable over 34 months. This latest acquisition gives Nobility Healthcare an anticipated annual revenue run-rate of approximately $4M, Digital Ally noted. In addition, it recently entered into a letter of intent to acquire two additional medical billing companies with combined expected annual revenues of $3.7M for purchase prices totaling $3.4M.

12:04 EDT Tesla CEO says Full Self-Driving Beta 10 goes out 'a week from Friday' - Tesla CEO Elon Musk said on Twitter that he is aiming for a wider release of its Full Self-Driving feature this month. "We should be there with Beta 10, which goes out a week from Friday (no point release this week)," Musk said in response to a user asking for an update on the public beta. "It will have a completely retrained NN, so will need another few weeks after that for tuning & bug fixes. Best guess is public beta button in ~4 weeks." Reference Link

12:00 EDT Doma Holdings falls -11.5% - Doma Holdings is down -11.5%, or -$1.03 to $7.93.

12:00 EDT Hippo rises 25.0% - Hippo is up 25.0%, or $1.31 to $6.54.

12:00 EDT IronNet rises 46.5% - IronNet is up 46.5%, or $7.75 to $24.41.

11:50 EDT Intel confirms plans to build new chip manufacturing facilities in Europe - Intel CEO Pat Gelsinger, during what the company identified as "his first in-person keynote since taking the helm of Intel in February," predicted that semiconductors will account for more than 20% of the total premium vehicle bill of materials, or BOM, by 2030. "That represents a staggering 5x growth rate over 2019's 4% figure. This comes amid increasing demand for semiconductors generally. Gelsinger predicted the total addressable market for automotive semiconductors will nearly double by the end of the decade to $115 billion, accounting for more than 11% of the entire silicon TAM. This trend is being driven by what Gelsinger called "the digitization of everything" and four superpowers - ubiquitous compute, pervasive connectivity, cloud-to-edge infrastructure, and AI - that are permeating the automotive and mobility industries," the company stated in a press release timed with the IAA Mobility event. Gelsinger "reminded the audience" at the event that Intel has plans to build at least two "new leading-edge" semiconductor factories in Europe with plans for future investments that could reach 80 billion euros over the next decade. He also detailed elements of the company's previously announced IDM 2.0 strategy and shared how those programs will apply specifically for the automotive and mobility industries in the European Union, the company stated. Reference Link

11:35 EDT Coinbase says apps may be experiencing errors - Coinbase said via Twitter, "We're aware transactions are currently delayed or cancelled at elevated rates and our apps may be experiencing errors. Our team is investigating the issue and we'll update here as soon as we know more."

10:58 EDT Zooplus confirms takeover talks with KKR - Zooplus (ZLPSF) confirmed recent media reports, pursuant to which it is also in discussions with KKR (KKR) with regard to a potential voluntary public takeover offer to the shareholders of the company. "At this stage, the outcome of the discussions with the interested parties KKR and EQT remains open," the company said in a statement. Both parties have approached Zooplus with a "qualified and credible financial as well as strategic proposal, and are therefore provided with access to the same level of information," it added.

10:37 EDT InflaRx up 10% after award of COVID-19 funding from Germany - Shares of InflaRx are up 25c, or 10%, to $2.84 in early trading in New York after Germany's Federal Ministry of Health and the Federal Ministry of Education and Research announced that they are promoting the joint development of drugs against COVID-19. According to a translation of a German-language joint statement from the ministries, Germany is "planning to support the projects of the coordinating companies AdrenoMed AG , Apogenix AG , Atriva Therapeutics GmbH , CORAT Therapeutics GmbH , InflaRX GmbH and the DRK Baden-Wurttemberg-Hessen gGmbH with a total of around 150 million euros." Reference Link

10:26 EDT Meggitt continues to recommend Parker offer, notes TransDigm doesn't intend bid - The Board of Meggitt (MEGGF) notes today's announcement by TransDigm Group (TDG) that it does not intend to make a firm offer for Meggitt. "Meggitt engaged on a constructive basis with TransDigm and its advisers in order to facilitate an offer by TransDigm and has provided TransDigm and Parker-Hannifin Corporation with equivalent access to both confirmatory due diligence information and management. In addition, in response to a request from TransDigm, further due diligence information was provided to both parties after the announcement of Parker's cash offer for Meggitt. The directors of Meggitt continue to recommend unanimously the offer by Parker to Meggitt shareholders announced on 2 August 2021. The Board of Meggitt believes the Parker Offer continues to represent an attractive proposition for Meggitt's shareholders and for its broader stakeholders, including its employees, pension schemes and customers, together with HM Government, for the long-term. The company confirms that the Court Meeting and the General Meeting to consider the Parker Offer will be held at Pilot Way, Ansty Business Park, Coventry, CV7 9JU, United Kingdom at 10:00 a.m. and 10:15 a.m. respectively, or immediately after the conclusion or adjournment of the Court Meeting, on 21 September 2021, further details of which are set out in the circular in relation to the Parker Offer, which was published on 16 August 2021. The Scheme Document also contains an expected timetable of principal events in relation to the Parker Offer," according to an announcement on behalf of Meggitt made by Marina Thomas, Company Secretary, to the London Stock Exchange.

10:18 EDT NeuroOne Medical Technologies receives FDA clearance for Evo SEEG System - The FDA has granted FDA 510(k) clearance to NeuroOne Medical Technologies for its Evo SEEG System, according to a notice posted on the FDA's website. NeuroOne's Evo Cortical Electrode technology is the result of a collaboration with the University of Madison-Wisconsin's Alumni Research Foundation and the Mayo Foundation for Medical Education and Research Reference Link

10:06 EDT National Instruments collaborates with EA Elektro-Automatik for battery test - NI announced it collaborated with EA Elektro-Automatik GmbH & Co. to offer bidirectional power supplies that support battery cycling and power-level test for electric vehicles. EA's best-in-class power supplies will be integrated into NI's software-connected toolchain as part of NI's power electronics offering to optimize battery test workflows. This joint effort accelerates the path to Zero Emissions by shortening time to market and improving safety and performance throughout the lifecycle of the battery.

10:02 EDT Duchossois Group agrees to sell The Chamberlain Group to Blackstone - The Chamberlain Group LLC announced that its owner, The Duchossois Group, has entered into a definitive agreement to sell Chamberlain Group to private equity funds managed by Blackstone. Following the close of the transaction, Chamberlain Group would remain a privately held company headquartered in Oak Brook, Ill. As part of the agreement, The Duchossois Group will retain meaningful ownership in the Company and two seats on the Company's Board of Directors following the close of the transaction. The transaction values Chamberlain Group at approximately $5B. The transaction is expected to close by the end of 2021, subject to regulatory approvals and customary closing conditions.

10:00 EDT Bright Scholar falls -7.4% - Bright Scholar is down -7.4%, or -25c to $3.15.

10:00 EDT Offerpad Solutions rises 25.1% - Offerpad Solutions is up 25.1%, or $2.17 to $10.80.

10:00 EDT IronNet rises 41.1% - IronNet is up 41.1%, or $6.85 to $23.51.

09:59 EDT Surrozen Inc (Class A Stock) trading resumes

09:54 EDT Surrozen Inc (Class A Stock) trading halted, volatility trading pause

09:47 EDT Huaneng Power falls -4.1% - Huaneng Power is down -4.1%, or -94c to $22.04.

09:47 EDT Offerpad Solutions rises 29.8% - Offerpad Solutions is up 29.8%, or $2.57 to $11.20.

09:47 EDT IronNet rises 50.9% - IronNet is up 50.9%, or $8.48 to $25.14.

09:45 EDT TransDigm decides not to make takeover offer for Meggitt - TransDigm Group (TDG) announced that it does not intend to make a firm offer for Meggitt (MEGGF). TransDigm Chairman Nicholas Howley stated, "We have long admired and studied the Meggitt business and believed that a combination between the two companies could provide value to investors of both companies. However, based on the quite limited due diligence information that was made available and the resulting uncertainties, TransDigm could not conclude that an offer of 900 pence per Meggitt share would meet our long-standing goals for value creation and investor returns. TransDigm and our advisers put substantial time, effort, resources and expense into evaluating a potential transaction. We reached a memorandum of understanding with the Meggitt Pension Plan trustees, arranged the necessary financing for the acquisition which we anticipated would position us roughly in the range of leverage levels that we have used historically for larger acquisitions, and communicated our willingness to make commitments to HM Government comparable to those offered by the other bidder for Meggitt. However, consistent with our disciplined approach to capital allocation, we make acquisitions only when we see a clear path to achieving our investment return goals with a reasonable degree of certainty."

09:43 EDT DuPont invests to expand DuPont Liveo Healthcare Solutions - DuPont announced continued investment in its DuPont Liveo Healthcare Solutions capabilities and manufacturing capacity. The company is pursuing execution of its healthcare investment roadmap to meet customer needs and the healthcare industry's rapid expansion. These investments target specialty healthcare markets, such as medical devices, biopharmaceutical processing and pharmaceutical solutions. "DuPont is committed to pursuing investments in healthcare capabilities to better serve customers around the world and enable them to grow, innovate and save lives," said Eugenio Toccalino, Global Business Director, DuPont Healthcare and Specialty Lubricants. "As a result of the global biologic production trend -- the reliability and adaptability of single-use components suppliers is more critical than ever. These continued investments are a testament to our long-term commitment to the healthcare industry". New over-molding press capabilities are scheduled to go online at HIMS in November 2021. The new press will allow expanded manufacturing of Over-molded Assemblies that improve high-purity fluid transfer and biopharmaceutical processes. In the second quarter of 2022, DuPont expects to begin to operate a second healthcare site - located in Cooper River, South Carolina. The site will ensure business continuity for our customers and offer a highly reliable and sustainable supply of healthcare solutions. Additionally, in the second half of 2022, DuPont plans to expand its global manufacturing footprint to better serve customers, by adding silicone pharmaceutical tubing production capacity in China dedicated to the region's fast-growing customers.

09:41 EDT Focus Universal Inc trading resumes

09:39 EDT enCore Energy, Azarga Uranium enter definitive agreement to combine - enCore Energy and Azarga Uranium announced that they have entered into a definitive arrangement agreement whereby enCore will acquire all of the issued and outstanding common shares of Azarga pursuant to a court-approved plan of arrangement. The Transaction consolidates an industry leading pipeline of exploration and development staged in-situ recovery focused uranium projects located in the United States, including the licensed Rosita & Kingsville Dome past producing uranium production facilities in South Texas, the advanced stage Dewey Burdock development project in South Dakota, which has been issued its key federal permits, the PEA-staged Gas Hills Project located in Wyoming, and a portfolio of resource staged projects throughout the United States. The combined company will possess a uranium resource base of 90.0 million pounds in the measured & indicated category, 9.9 million pounds in the inferred category, as well as 68.4 million pounds in the historic category. Under the terms of the Agreement, Azarga shareholders will receive 0.375 common shares of enCore for each Azarga common share held. The Exchange Ratio implies consideration of $0.71 per Azarga common share based on the closing price of the enCore common shares on the TSX Venture Exchange on September 3rd, 2021. Additionally, the Exchange Ratio will be subject to an adjustment mechanism at the closing of the Transaction. The Closing Exchange Ratio shall be equal to the greater of: the Exchange Ratio; or an exchange ratio calculated as $0.54 divided by enCore's 15-day volume-weighted average price prior to the closing of the Transaction, subject to a maximum Closing Exchange Ratio of 0.49 common shares of enCore for each share of Azarga outstanding. Pursuant to the terms of the Agreement, all of the issued and outstanding common shares of Azarga will be exchanged for common shares of enCore at the Closing Exchange Ratio. Outstanding and unexercised warrants and stock options to purchase common shares of Azarga will be adjusted in accordance with their terms based on the Closing Exchange Ratio. The Agreement includes standard deal protection provisions, including non-solicitation, right-to-match, and fiduciary out provisions, as well as certain representations, covenants and conditions that are customary for a transaction of this nature, along with a termination fee of $4 million payable to enCore in certain circumstances. The proposed Transaction will be effected by way of a plan of arrangement completed under the Business Corporations Act. The Transaction will require approval by at least 66 2/3% of the votes cast by Azarga shareholders and, if required by Multilateral Instrument 61-101, a simple majority of the votes cast by Azarga shareholders excluding certain interested or related parties, in each case by shareholders present in person or represented by proxy at a special meeting of the shareholders of Azarga to be called in connection with the Transaction. The Azarga Special Meeting is expected to be held in October or November 2021. An information circular detailing the terms and conditions of the Transaction will be mailed to the shareholders of Azarga in connection with the Azarga Special Meeting. All shareholders are urged to read the information circular once available, as it will contain important additional information concerning the Transaction. Closing of the Transaction is subject to the receipt of applicable regulatory approvals and the satisfaction of certain other closing conditions customary in transactions of this nature, including, without limitation, court and stock exchange approval. Closing of the Transaction is anticipated to occur in November 2021.

09:36 EDT Focus Universal Inc trading halted, volatility trading pause

09:34 EDT Stellantis appoints Christine Feuell as Chrysler Brand CEO - Stellantis announces that Christine Feuell, previously chief commercial officer at Honeywell Safety and Productivity Solutions, will join Stellantis as Chrysler brand CEO on September 13, reporting to CEO Carlos Tavares.

09:30 EDT Terreno Realty executes leases in Seattle - Terreno Realty announced that it has executed leases for a total of 57,000 square feet in Terreno Realty Corporation's SoDo Row redevelopment property in Seattle, Washington, with a provider of omnichannel logistics programs. The leases will commence on September 1 for 32,000 square feet and December 31 for 25,000 square feet and will expire March 31, 2027. These leases bring SoDo Row to 65% leased.

09:23 EDT Illumina partners with Merck to develop, commercialize tests for cancer mutation - Illumina (ILMN) and Merck (MRK) announced a partnership to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency, or HRD. Patients whose tumors are HRD-positive may be eligible for targeted treatment by a class of precision medicines called PARP inhibitors. This strategic partnership builds on an initial study conducted with Merck and leverages Illumina's relationship with Myriad Genetics (MYGN) to expand international access to the proprietary technology in Myriad's FDA approved myChoice CDx companion diagnostic test. Illumina will develop a new HRD CDx test for the EU and the UK to aid in the identification of ovarian cancer patients with positive HRD status who are eligible for treatment with LYNPARZA jointly developed and commercialized by Merck and AstraZeneca (AZN). In addition, Illumina will develop and commercialize a research use only HRD assay that will be add-on content for the TSO 500 RUO panel. Illumina plans to launch this product globally, excluding the United States and Japan.

09:22 EDT Paya Holdings announces strategic partnership with Paradigm - Paya has announced a strategic partnership with Paradigm, a software company focused on helping organizations throughout the building industry supply chain increase efficiencies and profitability. Through the partnership, Paradigm will launch Paradigm Payments, which will offer contractors, dealers, distributors, and manufacturers the ability to collect and process payments real-time, leading to greater back-office efficiencies and the opportunity to increase on-site sales.

09:19 EDT Matterport's Pro2 3D Camera available on Amazon in Europe - Matterport announced the expanded availability of its Matterport Pro2 3D Camera on six Amazon marketplaces. In addition to the US and Canada, the Pro2 is now available in the United Kingdom, Spain, Italy, and France. By expanding across Europe, Matterport provides greater access for its customers to purchase the company's industry-leading 3D capture technology so that they can realize the benefits of the Matterport spatial data platform and the power of digital twins.

09:19 EDT MasterCard 'expands' open banking reach with acquisition of Aiia - Mastercard announced it has entered into an agreement to acquire Aiia, a European open banking technology provider offering a direct connection to banks through a single API, allowing its customers to develop and launch new digital solutions that meet the needs of everyday life, work and play...The addition of Aiia anchors our European open banking efforts and allows us to continue to meet our customers where they are," said Craig Vosburg, Chief Product Officer, Mastercard. "As open banking continues to ignite innovation, we're committed to providing a unique set of technology platforms, data connectivity and infrastructure combined with data privacy and security principles. This will help fintechs and financial institutions innovate, gather feedback and scale faster and more effectively than ever to power smarter, more meaningful experiences."...We're excited to become a part of Mastercard and progress our journey of empowering people to bring their financial data and accounts into play - safely and transparently," said Rune Mai, CEO & Founder, Aiia.

09:17 EDT FDA approves Sensient Butterfly pea flower extract - Sensient Technologies announced that the U.S. Food and Drug Administration has approved a petition filed by Sensient's Color Group to add butterfly pea flower extract to the list of approved color additives in the United States. The addition of butterfly pea flower extract is a major milestone for the food industry since it closes an important gap in the natural color palette. The novel blue color is exceptionally heat stable and enables food and beverage brands to achieve a range of shades including bright blues, intense purples, and natural greens. "Closing the performance gap between FD&C colors and those from natural sources has long been a strategic priority for Sensient. The work on butterfly pea flower extract began more than a decade ago, and it is very gratifying to see the culmination of those efforts," stated Paul Manning, Chairman, President, and Chief Executive Officer of Sensient Technologies Corporation.

09:15 EDT INVO Bioscience announces official opening of second INVO Center in US - INVO Bioscience announced as the official opening for the company's second INVO Center in the United States, based in Atlanta, Georgia. This new joint-venture, named "Bloom Fertility, an INVO Center," will focus on patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell solution. The Atlanta-based INVO Center becomes the second INVO Center to open and will begin seeing patients immediately and perform initial INVOcell treatment cycles in the month of October 2021. Earlier this month, INVO Bioscience announced the opening of the first INVO Center based in Birmingham, Alabama. Additional INVO Centers are scheduled to open, including one in Monterrey, Mexico for this year as well as the San Francisco Bay Area.

09:13 EDT Ecolab announces expiration date results for exchange offers - Ecolab announced results as of the expiration date at 11:59 p.m., New York City time, on September 3, 2021, of its offers to certain eligible holders to exchange its outstanding notes of the four series described in the table for up to $500 million aggregate principal amount of its newly issued 2.750% Notes due 2055 and cash. The New Notes are a further issuance of, and are in addition to, the 2.750% notes due 2055 that Ecolab issued for cash on August 18, 2021, in the aggregate principal amount of $300 million. The Exchange Offers are being conducted on the terms and subject to the conditions set forth in a confidential offering memorandum dated August 9, 2021, and related letter of transmittal. Capitalized terms not otherwise defined herein are as defined in the Offering Memorandum. Ecolab previously announced that it extended the deadline to receive the Early Participation Amount beyond 5:00 p.m. New York City time on August 20, 2021 to the Expiration Date. Accordingly, holders of Old Notes validly tendered after the Early Participation Date but at or prior to the Expiration Date will receive the Total Exchange Consideration for each $1,000 principal amount of Old Notes. As of the Expiration Date, according to D.F. King & Co., Inc., the exchange agent for the Exchange Offers, the aggregate principal amount of the Old Notes validly tendered and not withdrawn in the Exchange Offers was $387,385,000, consisting of an aggregate principal amount of each series as set forth in the table below, which amount includes the $385,293,000 aggregate principal amount of the Old Notes validly tendered and accepted by Ecolab on August 24, 2021. Ecolab expects to accept all Old Notes tendered after the Early Participation Date and at or prior to the Expiration Date, and settlement of such tendered notes is expected to occur on September 8, 2021.

09:13 EDT MongoDB appoints Peder Ulander as Chief Marketing Officer - MongoDB announced the appointment of Peder Ulander as Chief Marketing Officer. Ulander will oversee the marketing organization including marketing operations, corporate communications, demand generation & field marketing, growth marketing and content marketing and will join MongoDB's executive leadership team. Ulander joins MongoDB from Amazon Web Services where he was Head of Enterprise and Developer Marketing.

09:11 EDT Alarm.com's Shooter Detection Systems to showcase solutions - Shooter Detection Systems, an Alarm.com company, will return to the Global Security Exchange show at the Orange County Convention Center in Orlando September 27-29, 2021. SDS will feature indoor gunshot detection solutions at the show, introduce attendees to new developments in enterprise-level software enhancements, and highlight Guardian Wireless, the Patent Pending wireless/battery-powered gunshot detection sensor and the latest innovation to join the Guardian Indoor Active Shooter Detection line of products. "These features were developed to create an enterprise customer solution complete with the elements IT teams demand," said Rich Onofrio, Managing Director for SDS. "These latest enhancements, combined with our ability to offer customers a pure on-premise solution without the need for external access - plus our association with Alarm.com - all keep SDS at the forefront of innovation in our field and the undisputed leader in enterprise and FedGov markets." This smart sensor for gunshots offers customers the flexibility to choose a wireless solution that utilizes SDS' proven technology for rapid detection and response to shooting incidents in buildings.

09:09 EDT Annex Cloud announces partnership with VTEX - Annex Cloud announced a partnership with VTEX to enable enterprises to deliver personalized, omnichannel customer experiences at scale-increasing customer lifetime value, improving retention and building emotional customer bonds that last. Annex Cloud's Loyalty Experience Platform, combined with VTEX's Digital Commerce Platform, enables brands to go to market faster, identify growth opportunities, optimize operations, serve up individualized interactions across the buyer's journey, engage customers across preferred channels, add meaningful value between transactions, identify and reward their best customers, drive repeat sales, reduce churn, and build lasting customer bonds.

09:07 EDT Gevo announces plans for hydrocarbon-process pilot unit - Gevo announced that it plans to install an alcohol-to-hydrocarbon process pilot unit at its facility located in Luverne, Minnesota. The pilot unit is being designed to produce market development quantities of sustainable aviation fuel, renewable premium gasoline, other renewable fuel products, as well as provide capability to supply market development quantities of chemical products. The installation is estimated to begin in Q3 2022 with startup demonstration production expected in Q4 2022. In addition, we expect to test and evaluate certain potential unit operations that may be incorporated into Gevo's state-of-the-art Net-Zero 1 production facility that is expected to begin production in 2024 in Lake Preston, South Dakota. Installation of the pilot unit at the Gevo-Luverne facility is part of the plan to use the facility as a technology development and piloting site. The pilot unit will also be used in training of employees for Net-Zero 1 and other future projects. Agri-Energy, LLC, Gevo's wholly-owned subsidiary that owns the Luverne Facility, rehired multiple former employees in the beginning of August, and is in the process of hiring additional employees to produce the isobutanol that is the feedstock for the hydrocarbon pilot unit. Additional operations staff will be required for the hydrocarbon production, though a certain number cannot yet be attributed to it.

09:07 EDT QueBIT partners with Anaplan to provide integrated planning, analysis - QueBIT Consulting announced that it has formally partnered with Anaplan. "By adopting Anaplan's technology platform, clients will be able to realize the bottom-line benefits of aligning financial, sales, operations, and supply chain targets to increase efficiency, forecasting accuracy and business agility," the company said. QueBIT's experience in requirements gathering, business modeling, user experience, performance tuning, and delivery assurance enhances the quality of the outcome, particularly for large enterprise clients with unique and complex data and systems landscapes.

09:05 EDT Metromile, Tokio Marine Holdings partner to reduce insurance fraud - Metromile Enterprise (MILE) announced Tokio Marine Group (TKOMY) is now using the artificial intelligence fraud-detection product Metromile DETECT across its property and casualty lines of business in Japan. By deploying Metromile DETECT, Tokio Marine believes it has succeeded in detecting suspected fraudulent claims with higher accuracy than leading U.S. insurers. Tokio Marine licensed Metromile Enterprise's no-code claims platform to improve the efficiency of its claims department and claims service. Tokio Marine analyzed claims payment and accident data with Metromile DETECT to detect fraudulent claims earlier and identify legitimate claims to be paid promptly with higher accuracy. Tokio Marine integrated Metromile DETECT with its existing claims infrastructure in less than four months, much faster than the typical six months to more than a year insurance carriers take to implement a new digital initiative. In its first month of deployment, Metromile DETECT equipped Tokio Marine with the ability to check all new claims for fraud, increasing customer and employee satisfaction with faster claims resolution. Metromile Enterprise's artificial intelligence scans claims in seconds and routes claims to the appropriate divisions, building a feedback loop with an insurer's investigative experts.

09:01 EDT Ballard Power, QUANTRON announce strategic partnership - Ballard and QUANTRON announce a strategic partnership for the development of hydrogen fuel cell electric trucks. Initial collaboration will focus on the integration of Ballard's FCmove family of heavy-duty fuel cell power modules into QUANTRON's electric drivetrain and vehicles. Fuel cell electric truck platforms currently in development include a 7.5t delivery truck, a 44t heavy duty truck and a municipal waste collection truck. Initial deployment of fuel cell electric trucks is scheduled for the second half of 2022. In Europe, various government subsidies and incentives will be available to vehicle fleet operators. Specifically, Germany has recently committed to covering up to 80% of conversion costs from internal combustions engines to alternative drives through the e-mobility support program. Robert Campbell, Chief Customer Officer of Ballard Power Systems: "Ballard is looking forward to collaborating with QUANTRON to accelerate the adoption of fuel cell technology for truck applications. The combination of both companies' expertise will deliver high performance hydrogen trucks to respond to the growing demand for zero emission vehicles from fleet operators and unlock new business opportunities for medium and heavy-duty fuel cell trucks in Germany. Ballard is bringing its 8th generation of heavy-duty fuel cell power module experience built upon over 85 million km's of road service from over 3,500 buses and trucks powered by our leading PEM technology today." Heavy duty vehicles have a higher impact on emissions and air pollution in cities than any other vehicle. The critical role of hydrogen and fuel cell technologies in the decarbonization of this sector has now been recognized in many European countries' hydrogen strategies. "The QUANTRON-Ballard collaboration will leverage the synergies between battery electric and fuel cell electric powertrains to enable a greener, faster and more cost effective decarbonization of the transportation," the company said.

08:58 EDT Amtech Systems reports record semiconductor segment bookings in August - Amtech Systems announced record bookings in its semiconductor segment for the month of August, totaling over $14M, representing strong demand in multiple end markets and applications. The systems booked in August will begin shipping in Q1 of 2022 and throughout the first half of FY22. The demand for BTU reflow ovens came in equal parts from the resurgence of the automotive electronics SMT sector globally and from ovens used for advanced packaging applications, including BTU's Pyramax TrueFlat configuration. The 300mm BDF diffusion furnaces, key for power semiconductor fabrication, also saw surging demand in the past month, with follow-on bookings from multiple 300mm customers. Additional bookings came from BTU's custom high-temp belt furnaces used for Direct Copper Bonding and other advanced applications.

08:54 EDT Envista announces intended sale of KaVo Treatment Unit, Instrument to Planmeca - Envista Holdings announced it entered into a binding agreement to sell its KaVo Treatment Unit and Instrument business to planmeca Verwaltungs GmbH for up to $455M, which includes a potential earn-out payment of up to $30M. The sale is expected to close at the end of 2021. The revenue of the business to be sold was approximately $357M and $317M in fiscal years 2019 and 2020, respectively. KaVo Treatment Unit & Instruments is a global developer, manufacturer, and supplier of industry defining dental treatment units and instruments. The business to be sold is part of Envista's Equipment & Consumables segment. Envista's Imaging business, which also currently uses the KaVo brand for select products, will stay with Envista as part of the Equipment & Consumables segment. It is expected that the KaVo Treatment Unit and Instrument business will be reported as a discontinued operation beginning with Envista's third quarter 2021 10-Q filing. The transaction is subject to the satisfaction of certain customary closing conditions, including the receipt of applicable regulatory approvals. The transaction is not subject to financing conditions or a shareholder vote.

08:49 EDT ZK International Group starts to supply ENN Energy - ZK International (ZKIN) announces that the company has started to supply pressed-type carbon steel pipeline to ENN Energy Holdings Limited (XNGSF) with an estimated total sales amount of $12.5M based on the estimated size of gassing projects ENN is engaging and estimated proportion ENN seeks to supply from the Company. The Company announced it was approved by ENN as a Qualified Stainless Steel Gas Pipe Supplier in May 2021, and now the Company has agreed with ENN on its procurement plan and started to supply for ENN's gassing infrastructure projects. Jiancong Huang, Chairman and CEO of ZK International, stated, "We are pleased that ENN has engaged us into its procurement plan, and we are glad to participate in the Clean Energy Initiative which aims to replace coal with clean energy. Over the past few years, we have adopted several national standards to standardize the construction and engineering criteria for the pressed-type carbon steel pipeline system, and we are pleased to see our quality and innovation have been recognized. ENN China strictly enforces a high standard of selecting its gas pipeline suppliers, considering the instances of gas leakage can be fatal. Therefore, ZK's experience and quality of the manufacturing are essential to ENN's commitment to adopting more carbon steel piping systems in its future residential gas pipeline projects from ZK. We believe as the Clean Energy Initiative starts to roll out across all northern cities of China, we will face a great opportunity with the increasing demand of the gas infrastructure."

08:46 EDT Victory Square Technologies says Fantasy 360 to start trading on CSE - Victory Square Technologies is pleased to announce that its portfolio company, Fantasy 360 Technologies Inc. d/b/a Immersive Tech has received final approval for listing from the Canadian Securities Exchange. The common shares of Immersive Tech will commence trading on the CSE under the symbol "VRAR" on September 8, 2021.

08:45 EDT Compass Diversified acquires Lugano Diamonds & Jewelry for $256M - Compass Diversified announced it has acquired Lugano Diamonds & Jewelry, a designer, manufacturer and marketer of high-end, one-of-a-kind jewelry, for an enterprise value of $256 million. Lugano will continue to be led by its current leadership team, and existing owners and management will retain a significant minority stake in the Company. Based in Newport Beach, California and founded in 2004, Lugano makes one-of-a-kind jewelry for some of the world's most discerning clientele. In addition to its product offerings, Lugano frequently partners with local, influential organizations to host and sponsor more than 100 equestrian, social and philanthropic events throughout the year. With a unique product catalogue, deep ties to its local communities and its intimate, salon-based sales model, Lugano builds long-lasting connections with its clients that have allowed it to achieve consistent growth for over 15 years.

08:42 EDT PPG expects lower Q3 sales volumes due to commodity supplies disruptions - PPG announced that it expects sales volumes in Q3 will be lower by $225M to $275M, compared to what the company anticipated at the start of the third quarter. PPG's sales volumes are being impacted by the increasing disruptions in commodity supplies; further reductions in customer production due to certain parts shortages such as semi-conductor chips; and continuing logistics and transportation challenges in many regions, including the U.S., Europe and China. In addition, raw material inflation for the third quarter is trending higher than previously communicated by about $60M to $70M. The coatings commodity supply disruptions have further deteriorated since the company's earnings announcement on July 19, due to several additional force majeure declarations and lower material allocations from certain suppliers. The company also continues to assess the full impact of Hurricane Ida, which could include additional supply chain effects. The company reported that aggregate global economic demand remains robust, and that inventories in many of the company's end-use channels are at very low levels. When supply conditions normalize, the company continues to expect strong sales growth into 2022. In addition, the company reported that it continues to make measurable progress implementing selling price increases to help offset the elevated raw material costs, and is seeking further increases. Overall price increases for the third quarter are estimated to be about 5% with similar contributions from both operating segments.

08:42 EDT Albireo Pharma sells priority review voucher for $105M - Albireo Pharma announced that it has entered into a definitive agreement to sell its Priority Review Voucher for $105 million. The PRV was granted to Albireo under a U.S. Food and Drug Administration provision that encourages the development of treatments for rare pediatric diseases. The Company received the voucher with the approval of Bylvay for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis. Albireo will receive a payment of $105 million upon the closing of the transaction, which is subject to customary closing conditions and is expected to occur following expiration of the applicable U.S. antitrust clearance requirements. Jefferies LLC acted as financial advisor to Albireo on this transaction and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. acted as legal advisor. The net sales proceeds expected from this transaction are in addition to the $186.3 million in cash, cash equivalents and short-term investments Albireo reported as of June 30, 2021.

08:39 EDT Horizon Therapeutics initiates trial evaluating Tepezza for TED treatment - Horizon Therapeutics announced that the first patient has been enrolled in a Phase 4 clinical trial evaluating the efficacy and safety of TEPEZZA for the treatment of chronic TED. TEPEZZA is the first and only medicine approved by the U.S. Food and Drug Administration for the treatment of TED - a serious, progressive and potentially vision-threatening rare autoimmune disease.TED begins with an acute ( phase where inflammatory signs and symptoms, such as eye pain, swelling, proptosis (eye bulging) and diplopia, progress over time.1,2 The disease then enters a chronic phase where inflammation is no longer present or has markedly diminished, but significant signs and symptoms may remain. "It is common for patients who are in the chronic phase of the disease to continue having debilitating symptoms, like eye pain and bulging, that interfere with daily living and require treatment," said Raymond Douglas, M.D., Ph.D., trial investigator and director of the Orbital and Thyroid Eye Disease Program, Cedars-Sinai Medical Center. "In a number of published case reports and analyses, TEPEZZA improved Thyroid Eye Disease symptoms, including eye bulging, when administered in the chronic phase. This trial will help us understand these observations in a controlled clinical setting." The primary efficacy endpoint is change from baseline at Week 24 in proptosis in the study eye. The trial will also assess proptosis responder rate, diplopia responder rate, change in orbital pain, change in muscle volume and change in the Graves' Ophthalmopathy Quality of Life questionnaire appearance and visual functioning subscales. Proptosis non-responders who have completed the treatment period may choose to enter an open-label extension period where they will receive eight infusions of TEPEZZA. More information about the trial, including full eligibility criteria, can be found at clinicaltrials.gov .

08:38 EDT Neuronetics, Zion Healing announce first franchise model for TMS clinics - Neuronetics and Zion Healing announced a new agreement under which Neuronetics will be the exclusive supplier of TMS equipment to Zion Healing, Inc. and its franchisees. Zion Healing, Inc. is one of the first and only companies to offer a scalable model for franchising of Mental and Behavioral Health Clinics. NeuroStar Advanced Therapy is a non-invasive, non-drug treatment option that uses transcranial magnetic stimulation to target key areas of the brain that are underactive in people with depression. NeuroStar is the leading TMS treatment for depression in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar has been proven to be safe and effective with over 4 million treatments delivered to 110,000 patients to date.

08:35 EDT Group of CytoDyn stockholders responds to 'misleading' company news release - A group of long-time stockholders of CytoDy that has nominated five highly experienced director candidates to serve on the Company's Board of Directors today responded to a news release issued by CYDY on September 3. that completely misrepresented a voluntary stipulation filed by the Nominating Stockholders in the litigation initiated by the Company in the United States District Court. This misrepresentation is a blatant attempt to quash shareholders' ability to vote for an alternate slate of directors. The facts are that the Nominating Stockholders voluntarily corrected an unintentional oversight by filing two public communications with the SEC, and submitted to the court a short stipulation acknowledging their continued commitment to comply with the securities laws as a showing of good faith, which they asked the Court to so-order. The Company's release is just another example of its desperation and attempt to distract shareholders from the Board's and management's mismanagement of CYDY. The Nominating Stockholders are confident that the shareholders of CYDY can see past these continued attempts by the Company to create noise and urge them to focus on the very significant issues facing the Company. It remains highly disturbing that CYDY continues to expend very significant resources to entrench itself and prevent shareholders from voting for an alternative slate of directors. Attempting to twist the continued good faith actions of the Nominating Stockholders in litigation that CYDY itself initiated simply illustrates desperation and fear to allow shareholders to make their rightful choice.

08:35 EDT Anixa Biosciences appoints Pamela Garzone as Chief Development Officer - Anixa Biosciences announced the appointment of Pamela Garzone, Ph.D., as Chief Development Officer. Dr. Garzone will oversee Anixa's vaccine and therapeutic development programs and will report to the CEO. Garzone is a senior pharmaceutical executive with over 25 years of diverse experience in the industry.

08:34 EDT Ageagle Aerial Systems' MicaSense to expand line of sensor solutions - AgEagle Aerial Systems announced that its wholly-owned subsidiary, MicaSense, plans to expand its line of sensor solutions with the launch of its next generation of high performance multispectral sensors, providing the best economics, highest resolution and most extensive data analysis capabilities of any multispectral drone sensors offered in the market today. Over the next three months, MicaSense will commence the global roll-out of its next generation multispectral sensors, unveiling detailed specifications, functionality and user benefits upon launch of each new sensor. In addition, MicaSense will be releasing a new firmware update that will provide users of Altum and RedEdge-MX Skyport integrations with high quality and precisely geotagged multispectral data. The Skyport connector facilitates data transmission, communication and precision time and position synchronization between the drone and MicaSense sensors, requiring only a firmware update to access centimeter-level GPS accuracy on supported DJI drones.

08:32 EDT 3D Systems appoints Brent Stucker as chief scientist - 3D Systems (DDD) is pleased to announce that Dr. Brent Stucker is joining the company to serve in the newly created role of Chief Scientist. Dr. Stucker was previously employed by Ansys (ANSS), where he served as Director of Additive Manufacturing and as Distinguished Engineer. He joined Ansys following their acquisition of 3DSIM in 2017, a software simulation company that he co-founded and led as CEO. 3DSIM was the first AM simulation company and a pioneer in the use of simulation for process control and optimization of 3D printing.

08:30 EDT Farmmi wins new order for export to Southwest Asia - Farmmi announced the company's subsidiary Zhejiang Forest Food, won a new product order for its popular dried whole Shiitake mushrooms. The customer will export Farmmi's Shiitake mushrooms to Southwest Asia. Yefang Zhang, Farmmi's Chairwoman and CEO, commented, "Our latest win comes from one of our long-term customers, with a far reaching business network. By successfully supporting such important relationships, we are able to leverage our many partners' logistics investments and established distribution networks. This allows us to focus on our direct farm and collective networks to ensure we have adequate supply on hand to meet increased customer demand for our high-quality agricultural products. In addition to the well-established nutritional benefits of mushrooms, we are seeing more interest in the inherent cultivation benefits given the low water requirements, which is critical in geographic markets worldwide."

08:29 EDT Swedish Orphan Biovitrum announces publication of Phase 3 anakinra study results - Swedish Orphan Biovitrum announced that Nature Medicine has published results from the investigator-sponsored Phase 3 SAVE-MORE randomized controlled trial evaluating anakinra plus standard of care versus placebo plus SOC in hospitalized adult patients with COVID-19 pneumonia as measured by the 11-point World Health Organization Clinical Progression Scale at day 28. The study demonstrated that patients treated with anakinra were significantly more improved than those treated with placebo. Additional analyses showed that early and targeted use of anakinra, in addition to current SOC, reduces risk of death, reduces ICU admission and increases likelihood of full recovery in hospitalized COVID-19 patients with poor prognosis due to risk of severe respiratory failure. The SAVE-MORE study, conducted by the Hellenic Institute for the Study of Sepsis, is among the first large, pivotal randomized controlled trials to specifically evaluate a patient population at risk of progressing to critical state and demonstrate considerable benefit of earlier intervention for the prevention of disease progression and death. Co-administered treatments were similar between the two arms of the study and included dexamethasone, anticoagulants and remdesivir. The study results were previously reported in May.

08:24 EDT NuProbe Global adopts Bionano's Saphyr System to develop products - Bionano Genomics announced that NuProbe Global, a global molecular diagnostics company based in Shanghai, China and Houston, Texas, has adopted Bionano's Saphyr system for optical genome mappin to integrgate their Quantitative Amplicon Sequencing and Blocker Displacement Amplification technologies for research and product development in the fields of reproductive health and oncology liquid biopsies.

08:22 EDT Research Frontiers' SPD-SmartGlass Tech debuts at IAA Munich Auto Show - The company said, "If you want to see how smart your glass can be, you only have to walk through the IAA Munich Auto Show this week to see SPD-SmartGlass technology at work to make cars, trains and buses more energy-efficient, safer, comfortable and fun to ride in. This has been made possible by Research Frontiers' patented SPD light-control technology and Gauzy Ltd, a material science technology company. Gauzy is a strategic investor and licensee of Research Frontiers, which is the inventor of patented SPD-SmartGlass light-control technology. Gauzy, presenting in Hall A1, Booth 93, is showcasing both SPD and its specialty PDLC nanotechnologies at IAA this week. Geared towards displaying how smart glass is driving the future of advanced automotive glazing through dynamic light control embedded directly in interior and exterior glass, each demonstrator represents how active glass with SPD and PDLC can support greater functionality, user experience, comfort, and optimized space - while upholding future facing aesthetics and design. SPD, presented with and without invisible segmentation, is being shown in a sunroof application, as well as an integral part of the new era in displays that turn transparent when paired with transparent OLED displays powered by LG Display, and projection technologies. Partners of Gauzy being displayed at the Gauzy booth include LG Display, Texas Instruments, and Vision Systems, longtime valued partner of both Gauzy and Research Frontiers. In addition to the innovations exhibited at Gauzy's booth, Gauzy's technologies at IAA are also being shown by a number of other exhibitors including Sekisui, Brose, and a special OEM to be announced from the show floor during the second half of the show."

08:21 EDT Washington Prime announces intention to delist common stock from NYSE - Washington Prime announced its intention to voluntarily delist from the New York Stock Exchange its shares of common stock. On or about September 20, the company intends to file a Notification of Removal from Listing on Form 25 with the U.S. Securities and Exchange Commission, and it is expected that the last day of trading of the common stock and preferred stock on the NYSE will be on or about September 29. It is expected that the company's common stock and preferred stock will be removed from listing and registration on the NYSE at the opening of business on or about September 30. Because the company's common stock and preferred stock will no longer be publicly held upon its expected emergence from its previously announced Chapter 11 proceedings, the company believes that the costs and expenses associated with the continued listing of the common stock and preferred equity, and the corresponding governance and filing requirements, are not economically justified. The company does not intend to arrange for listing or registration of the common stock or preferred stock on another stock exchange and does not plan to take any action to facilitate trading on an over-the-counter market.

08:19 EDT Umpqua Holdings promotes Anderson to Chief Administrative Officer - Umpqua Holdings announced that Jacquelynne Bohlen, CFA, will head investor relations for the bank. She joins Umpqua from Keefe, Bruyette & Woods. Bohlen will report directly to Ron Farnsworth, chief financial officer, and will oversee Umpqua's relationships with shareholders and the larger investment community. Bohlen replaces Drew Anderson, who has been promoted to a new position as Umpqua's chief administrative officer, reporting directly to CEO Cort O'Haver. Anderson's responsibilities include leadership and oversight of enterprise operational functions, including teams focused on data and analytics and the enterprise portfolio management office. He will also chair the company's executive operating committee.

08:18 EDT Live Oak Bancshares converts deposit customers to Finxact cloud-based core - Live Oak Bancshares announced it successfully converted Live Oak Bank deposit customers from its legacy core system to the Finxact cloud-based core. The conversion of more than 60,000 customer accounts, the largest conversion Finxact has made to date, is a major milestone in converting all Live Oak Bank customers to Finxact's leading core as a service platform, giving Live Oak Bank an unencumbered banking foundation that allows it to build products and services using next-generation technology.

08:17 EDT Universal Corporation to acquire Shank's Extracts - Universal announced that it has entered into a definitive agreement to acquire Shank's Extracts. Following the close of the transaction, Shank's will operate as part of Universal's plant-based ingredients platform, which includes Silva International and FruitSmart. "This agreement with Shank's marks another important step forward in Universal's efforts to identify and execute on opportunities that broaden and enhance our plant-based ingredients platform," said George Freeman, III, Chairman, President and Chief Executive Officer of Universal Corporation. "The Shank's acquisition fits squarely in our new platform and our capital allocation strategy, bolstering our offerings for customers and expanding our value-added services by adding flavors, custom packaging and bottling, and product development capabilities." Universal Corporation expects the transaction to close in calendar-year fourth quarter, subject to customary closing conditions, and anticipates the acquisition will be accretive to earnings in fiscal year 2023. Following the close of the transaction, the existing management team will continue to run the business and report to J. Patrick O'Keefe, Senior Vice President of Universal Global Ventures. Universal Corporation expects to fund the transaction with cash on hand and borrowings under its committed revolving credit facility.

08:15 EDT TransDigm update on approach to Meggit - TransDigm Group (TDG) announced that after careful consideration, it does not intend to make a firm offer for Meggitt (MEGGF). TransDigm Chairman W. Nicholas Howley stated, "We have long admired and studied the Meggitt business and believed that a combination between the two companies could provide value to investors of both companies. However, based on the quite limited due diligence information that was made available and the resulting uncertainties, TransDigm could not conclude that an offer of 900 pence per Meggitt share would meet our long-standing goals for value creation and investor returns. TransDigm and our advisers put substantial time, effort, resources and expense into evaluating a potential transaction. We reached a memorandum of understanding with the Meggitt Pension Plan trustees, arranged the necessary financing for the acquisition which we anticipated would position us roughly in the range of leverage levels that we have used historically for larger acquisitions, and communicated our willingness to make commitments to HM Government comparable to those offered by the other bidder for Meggitt. However, consistent with our disciplined approach to capital allocation, we make acquisitions only when we see a clear path to achieving our investment return goals with a reasonable degree of certainty."

08:13 EDT Future FinTech signs definitive agreement to purchase Khyber Money Exchange - Future FinTech announced that on September 1, 2021, the company signed a definitive agreement to acquire 100% of the equity of Khyber Money Exchange from Rahim Shah. According to the Agreement, the company will acquire 100% of the equity of Khyber Exchange at a purchase price of approximately $820,170. The company engaged in extensive operational, legal and financial due diligence in order to reach this Agreement. Khyber Exchange is regulated by the UK Financial Conduct Authority; the acquisition needs to be approved by the FCA before its formal closing. Shanchun Huang, Chief Executive of Future FinTech, commented, "We are pleased about this acquisition as it further extends our fintech footprint and further diversifies our geographical reach. We believe that money payment services are a high margin business that will enable us to capitalize upon an increasing level of international business transactions and money flows. We believe that it will be synergistic with other financial service businesses that we are developing."

08:11 EDT Candel Therapeutics completes enrollment in Phase 2 trial of CAN-2409 - Candel Therapeutics announced that it has completed patient enrollment for its pivotal phase 3 study of CAN-2409 immunotherapy in patients with intermediate-high risk localized prostate cancer. This placebo-controlled, randomized clinical trial is evaluating CAN-2409 treatment in combination with valacyclovir added to upfront standard of care external beam radiation therapy for patients with localized prostate cancer compared to standard of care radiation therapy alone. The primary endpoint of the study is disease-free survival. Secondary endpoints include prostate cancer specific survival, overall survival, freedom from biochemical failure, patient reported health-related quality of life, and safety.

08:11 EDT Progress Software to unveil new capabilities at ChefConf 2021 - Progress announced the availability of enhancements to the Progress Chef portfolio that span multi-cloud trust and compliance, operator experience and productivity, and cloud "as a service" deployment flexibility. Progress will highlight these capabilities at ChefConf 2021, the virtual version of its 10th annual Chef community and user conference held today through September 9, with a focus on helping teams accelerate their DevOps journeys. Enterprise trends are driving rapid DevSecOps innovation. As organizations move more workloads into the cloud, the need for security and compliance automation has accelerated. IT teams must continuously deliver change in their technology environments while maintaining adherence to business policies ranging from governmental regulations to security best practices. Chef technology enables a policy-as-code approach to automate the implementation, validation and governance of business policies. In line with these trends, and with the goal of helping more organizations adopt and gain value from DevSecOps practices and technology more easily, Progress is announcing the following new Chef features: Multi-cloud Trust and Compliance - Chef Compliance Automation for Cloud Resources extends support across major cloud providers AWS, Azure, and GCP with extensive new certified Chef Premium Content plus support for cloud-specific best practices including integration with Azure Policy. Enhanced Operator Productivity - Chef technology continues to support the DevSecOps journey by providing important enhancements to Chef Enterprise Automation Stack, including tighter integration between compliance and infrastructure automation, support for Windows patch management, integration with leading secrets management tools, improvements to Chef Workstation and Chef Test Kitchen to enable test-driven development and new, more powerful infrastructure operations dashboards. Deployment Flexibility - To ease adoption and bring the power of Chef to more organizations, Progress has launched SaaS-based access to its Chef product suite as a beta offering, now provides access to Chef products through the AWS and Azure Marketplaces, and launched an all-new Chef Managed Services program designed to eliminate the burden of managing an organization's own Chef deployment.

08:10 EDT Paramount Group signs leases aggregating 279,000 square feet in Manhattan - Paramount Group announced that it signed leases aggregating 279,000 square feet at 1301 Avenue of the Americas, a 1.7M square-foot trophy office building, located between 52nd and 53rd Streets in Midtown Manhattan. The leases include a new 167,000 square foot lease with Credit Agricole CIB, a global corporate and investment bank, and a 112,000 square feet renewal and expansion lease with SVB Leerink, an investment bank specializing in healthcare and life sciences. The signing of these leases backfills approximately 190,000 square feet of existing vacancy on floors six, eight, and nine at 1301 Avenue of the Americas, which was 71.5% leased as of June 30.

08:09 EDT Document Security's Impact BioMedical synthesized first Quantum-based compound - After more than a year of research and development, Impact BioMedical, Inc., and its research partner Global Research and Discovery Group Sciences announce that its first Quantum-based compound was successfully synthesized. The compound synthesized is an adjuvant which enhances a body's immune response to a foreign antigen and is being sent to a major University for testing. Impact BioMedical, Inc., a wholly owned subsidiary of Document Security Systems, and GRDG Sciences initiated the research project called Quantum in Summer 2020. The purpose of the project was two-fold: to forge a new frontier by exploring new methods for developing medicinal protocols that work more efficiently, thereby encouraging further research and development across the pharmaceutical industry, while at the same time mitigating a projected patent cliff crisis. The Quantum technology is designed to enhance existing therapeutics by looking beyond current molecular enhancement techniques such as molecular substitution, halogenation, prenylation and other biological enhancement methods typical of present therapeutic development schema. This marriage of quantum and molecular mechanics essentially created a classic example of bionics that theoretically increases the efficacy against a variety of diseases. The increase in the quantum molecule's therapeutic activity is due to alterations in the intermolecular state, which yields a molecule with increased reactivity to ligand interactions with significantly lower degradation rates. In short, the Quantum molecule will possess both hyper-reactivity as well as hyper-persistence. GRDG Chief Scientific Advisor Dr. Roscoe M. Moore, Jr., the retired United States Assistant Surgeon General and former Epidemic Intelligence Services Officer at the U.S. Centers for Disease Control said that this step toward quantum molecules could pave the way for new medical breakthroughs.

08:08 EDT UGI Corporation adds second renewable natural gas project in New York - Cayuga RNG announced that it has entered into an agreement to develop its second project to produce renewable natural gas, or RNG, in upstate New York. This is in addition to the previously announced Spruce Haven Farm initiative. Cayuga RNG is a joint venture of UGI Energy Services, a subsidiary of UGI Corporation and Global Common Energy. As previously announced, Cayuga RNG's first project is being developed at the Spruce Haven Farm located in Cayuga County in the Finger Lakes region of New York. The project incorporates an existing anaerobic digester that generates biogas, which is used to produce renewable electricity, and is expected to be completed in the second half of calendar year 2022. Cayuga RNG contracted with Martin Construction Resource, a supplier of RNG equipment, for the gas upgrading equipment at Spruce Haven. Cayuga RNG's second project will be located at Allen Farms, which is approximately five miles from Spruce Haven. Allen Farms has contracted with Cayuga RNG to supply dairy waste that will serve as the feedstock for renewable natural gas. The project will include the construction of an anaerobic digester and a combined heat and power project. Once completed in the second half of calendar 2022, the project is expected to produce 85M cubic feet of environmentally friendly RNG each year. Cayuga RNG is actively pursuing several other projects in the region. GHI Energy, a UGIES subsidiary, will be the exclusive off-taker and marketer of RNG for Cayuga RNG.

08:07 EDT Hims & Hers CFO Lee to step down, company backs previous financial views - Hims & Hers Health announced that Spencer Lee plans to step down from his role as the company's Chief Financial Officer. Lee, who joined the company in March 2019, will lead a six month transition plan and continue to support the company until a new CFO is appointed to ensure a smooth transition. The search for a new Chief Financial Officer has begun and is being led by Co-Founder and CEO Andrew Dudum and Board Member and Audit Chair, David Wells, the former CFO of Netflix. "It has been an honor to work at Hims & Hers, such a transformative and impactful company, during a critical period of growth," said Lee. "Andrew and I agree that given the strong financial position of the Company and the exciting growth initiatives now kicking off, the time is right to begin the process of finding a new financial leader to guide the company in its next stage." "Spencer has been a valuable partner for Hims & Hers as we have achieved several significant company milestones, including our transition to a publicly traded company, two completed acquisitions and strong quarterly earnings for the last three quarters," said Dudum. "Spencer, the leadership team and I will work closely to manage a smooth transition over the next six months as we identify a new CFO to partner in bringing our next chapter of growth and ambitious goals to life." This announcement follows Hims & Hers' strong reported Q2 earnings in 2021. In 2020, full year revenue grew by 80% year-over-year. In Q1 and Q2 of 2021, quarterly revenue grew year-over-year by 74% and 69%, respectively, exceeding the company's previous guidance for each such quarter and resulting in the company sequentially increasing its full-year revenue guidance. As of Q2, Hims & Hers has grown subscriptions year-over-year by 76% to 453,000 as it continues to focus-in on expanding core services and investing in new ones. The company also recently announced the appointment of its first Chief Growth Officer. Hims & Hers also reaffirmed its financial guidance for the third quarter and full year 2021, which it provided in connection with the announcement of the company's second quarter 2021 financial results on Aug. 11, 2021.

08:06 EDT Voip-Pal.com announces updates on pending patent litigations - VoIP-Pal.com Inc. (VPLM) announced its updates concerning its pending patent litigations: Litigation in the Western District of Texas: On September 3, 2021, the U.S. District Court for the Western District of Texas, Waco Division, denied VoIP-Pal's application and motion to temporarily restrain and enjoin Defendants Apple (AAPL), AT&T (T), and Verizon (VZ) from pursuing their 2021 declaratory-judgment actions filed in the Northern District of California involving VoIP-Pal's Mobile Gateway Patents. The Court found no authority for issuing a temporary restraining order and preliminary injunction and did not believe that such a remedy was appropriate under the first-to-file rule. . Furthermore, the WDTX Court denied the defendants' request to stay VoIP-Pal's existing lawsuits in the WDTX involving the Mobile Gateway patents, pending the NDCA's decision on whether the defendants' declaratory judgment cases in NDCA against these patents were related to previous cases. Notably, the WDTX Court rejected the defendants' argument that the 2021 Mobile Gateway cases in WDTX were similar the earlier cases VoIP-Pal had litigated in the NDCA. Litigation in the Northern District of California: On August 25, 2021, the NDCA court denied Apple's and AT&T's administrative motions to consider whether their newly filed declaratory-judgment actions should be related to their previously filed declaratory-judgment actions. On August 26, 2021, the NDCA also issued an order denying that Verizon's newly filed declaratory-judgment action is related to Verizon's previously filed declaratory-judgment action. There were also several developments with respect to the declaratory judgment suits of Apple, AT&T and Twitter in the NDCA seeking non-infringement and invalidity of U.S. Patent No. 10,218,606 and U.S. Patent No. 9,935,872, i.e., 5:20-cv-02460-LHK, 5:20-cv-02995-LHK, and 5:20-cv-02397-LHK. The NDCA court denied VoIP-Pal's motions to dismiss the Apple and AT&T cases based on VoIP-Pal's covenant not to sue on the '606 Patent and '872 Patent because the covenant was considered insufficiently broad to divest the NDCA Court of subject-matter jurisdiction. However, the NDCA Court dismissed Twitter's action. U.S. Supreme Court : On September 3, 2021, the Company filed its reply brief in support of its petition for a writ of certiorari filed with the Supreme Court of the United States on June 25, 2021, in its ongoing appeal of an NDCA order invalidating U.S. Patent Nos. 9,537,762, 9,813,330, 9,826,002 and 9,948,549. In particular, VoIP-Pal has asked the Supreme Court to hold its case pending resolution of another case pending before the Court, American Axle & Manufacturing, Inc. v. Neapco Holdings LLC, No. 20-891, which presents similar legal issues, including whether it is improper to apply 35 U.S.C. Section112 considerations to determine whether a patent claims eligible subject matter under 35 U.S.C. Section101. VoIP-Pal's petition is now fully briefed and awaits disposition.

08:03 EDT Cabaletta Bio appoints Michael Gerard as general counsel - Cabaletta Bio (CABA) announced that Michael Gerard has been appointed general counsel. Mr. Gerard most recently served as Associate General Counsel at Spark Therapeutics, a member of the Roche Group (RHHBY).

08:03 EDT Universal Technical, BMW partner to add new program for service members - Universal Technical Institute (UTI) and BMW of North America (BMWYY) are partnering to add a program for service members at the U.S. Army's Fort Bragg, N.C. base. The BMW MSTEP, or Military Service Technician Education Program, provides training for new career opportunities for service members transitioning from military service back into civilian life. The BMW MSTEP program was first launched at Marine Corps Base Camp Pendleton in Southern California in 2018. The 16-week BMW technical education program features a specialized on-base curriculum and hands-on technical training on diagnostics and technologies unique to the BMW brand. Upon graduation, BMW assists the new technicians with employment at authorized U.S. dealers. There are currently more than 7,000 BMW technicians across the network, and more are needed every year, especially those trained by the company itself.

08:01 EDT Oxford Lane estimates August NAV $6.69-$6.79 - Oxford Lane Capital announced the following net asset value estimate as of August 31, 2021. Management's unaudited estimate of the range of the NAV per share of our common stock as of August 31, 2021 is between $6.69 and $6.79. This estimate is not a comprehensive statement of our financial condition or results for the month ended August 31, 2021. This estimate did not undergo the Company's typical quarter-end financial closing procedures and was not approved by the Company's board of directors. We advise you that our NAV per share for the quarter ending September 30, 2021 may differ materially from this estimate, which is given only as of August 31, 2021. As of August 31, 2021, the Company had approximately 115.1 million shares of common stock issued and outstanding.

07:56 EDT Marathon Gold says detailed engineering work ongoing at Valentine Gold Project - Marathon Gold provides an update on ongoing development activities at the Valentine Gold Project located in central Newfoundland. Detailed engineering work is ongoing and the results are being incorporated into a control budget and schedule for the Project that would support a potential construction decision later this year. This work is being undertaken by Marathon's project execution team and Ausenco Engineering Canada. In August 2021, Marathon and Ausenco entered into a Memorandum of Understanding for a fixed-price Engineering, Procurement and Construction contract for Project construction to be finalized later this year. The EPC contract would relate principally to the Project's mill and major facilities, representing approximately 50% of the Project's overall scope. Outside the EPC scope, Marathon contemplates owner-operated development of the Project's major earthworks, tailings management facility, site services, and infrastructure, as well as owner-operated mining operations. In July 2021, Marathon entered into an Implementation Agreement with NL Hydro for the construction of a 49.5 kilometre long 69kV powerline to the Project from the Star Lake generating station. On August 18, 2021 this powerline and its connection to the provincial power grid was approved by the NL Public Utilities Board. An Environmental Preview Report has been requested of NL Hydro by an inter-departmental committee of the NL government and will commence shortly based on guidelines expected to be issued this month. Detailed engineering for the powerline and an associated substation at Star Lake has already commenced under the terms of the Implementation Agreement. Additionally, Marathon has completed procurement of a permanent camp of 350 beds and is finalising procurement in the areas of mobile equipment, major earthworks contracting and site communications. Onsite geotechnical and hydrogeological work is ongoing in support of detailed engineering for the Project's tailings management facility which is being undertaken by Golder Associates Limited. Access road and bridge upgrades are scheduled to commence following release from the Project's Environmental Assessment.

07:53 EDT Hyzon Motors announces ZeroAvia placed order for Hyzon's fuel cells - Hyzon announced that ZeroAvia has placed an order for Hyzon's next generation, high-performance lightweight fuel cell. ZeroAvia will evaluate the fuel cell for use in its zero-emission aircraft development program, which focuses on hydrogen-electric solutions. ZeroAvia selected Hyzon's fuel cell stack for this evaluation due to its power density. ZeroAvia will test the fuel cell stack through simulated airplane duty cycles. These tests will include customary power needs such as take-off, cruising, landing and taxiing, as well as more strenuous circumstances including rapid changes in altitude and other ambient conditions. Once the fuel cell stack has been validated in a ground test program, the next step will be to test them in flight.

07:51 EDT Ayr enters agreement to acquire Cultivauna for $20M upfront consideration - Ayr Wellness announced that it has moved to a definitive agreement for its previously announced plan to acquire Cultivauna, LLC, the owner of Levia branded cannabis infused seltzers and water-soluble tinctures. Ayr intends to purchase 100% of the equity interests of Cultivauna, LLC. The terms of the transaction include $20 million in upfront consideration, made up of up to $10 million in cash with the remainder in stock. An earn-out payment of up to an additional $40 million will be paid in shares based on the achievement of revenue targets in 2022 and 2023. Levia Cannabis Infused Seltzer is currently available in Massachusetts in three experiences and flavors: "Achieve" Raspberry Lime; "Celebrate" Lemon Limel "Dream" Jam Berry. Each flavor is available in 12-ounce slim cans and contains 5 mgs of THC. Levia is also available in water soluble tinctures in the same formulations. Levia uses a proprietary technology which provides for rapid onset of the effects of THC, typically 15-20 minutes and the effects last up to 3 hours, allowing for a more consistent consumption experience than many edible products. The acquisition is subject to customary closing conditions and regulatory approvals. The acquisition is expected to close by the end of 2021.

07:49 EDT SL Green Realty launches leasing at residential tower at 7 Dey Street - SL Green Realty and Douglas Elliman announced the launch of leasing at 7 Dey Street. A 34-story, mixed-use building in Lower Manhattan, the property will be the neighborhood's first development built under the Affordable New York Housing Program.

07:47 EDT MAG Silver reports Phase 1 Deer Trail drilling results - MAG Silver is pleased to report results from Phase 1 drilling on its Deer Trail Carbonate Replacement Deposit Project in central Utah, USA. Phase 1 saw the completion of three holes drilled from surface spaced along a 1.5 km long corridor. Phase 1 successfully fulfilled all three of its planned objectives by: Confirming the presence of a thick section of more favorable carbonate host rocks below the Deer Trail Mine; Confirming and projecting two suspected mineralization feeder structures to depth; and Intercepting high-grade mineralization related to those structures in host rocks below what was historically known. Notably, all three holes bottomed within multi-phase porphyritic granitoids affected by later sericite-pyrite alteration with modest Copper and Silver mineralization along their upper contacts. The overall features suggest that this mineralization was sourced from a later intrusive phase. The principal goal of Phase 1 drilling was to locate the Redwall Limestone, a thick, clean limestone unit hypothesized to be a more favorable host rock than the thinly layered Callville Formation, which hosts the deepest historically known mineralization in the mine area. The likely presence of the Redwall was indicated by regional occurrences and all three holes cut 215 m - 320 m of highly altered Redwall before bottoming in granitoid intrusions. All three holes cut high-grade sulphide mineralization in/near projected feeder structures within the Callville before reaching the Redwall. DT21-02 intercepted 0.50 m of sulphides grading 426 grams per tonne, Gold, and 17.1% Lead plus Zinc within a 3.5 m breccia zone along the Red Fissure Fault; principal feeder to the historic Deer Trail Manto. DT21-03 cut 1.90 m of manto-style sulphides grading 952 g/t Silver, 38.2 g/t Gold, and 9.2% Lead plus Zinc close to the Wet Fault, a principal feeder to the 3400 Area manto zone. DT20-01 was designed simply to locate the Redwall at shallow depth, but before reaching the Redwall, it cut a ~20 m feeder zone in the Callville containing a 2.30 m (core length) mineralized strand that reported 1.0 g/t Gold and 101 g/t Silver. Phase 2 drilling commenced on August 20, 2021. The first hole of Phase 2 is an offset of DT21-03 designed to test the Wet fault 150 m deeper where it cuts through the Redwall.

07:43 EDT Westhaven Gold announces drill results from Shovelnose property - Westhaven Gold is pleased to announce drill results from its ongoing drill campaign at its 100% owned 17,623-hectare Shovelnose gold property. Shovelnose is located within the prospective Spences Bridge Gold Belt, which borders the Coquihalla Highway 30 kilometres south of Merritt, British Columbia. Westhaven is reporting assays for 17 holes from its ongoing drill campaign at Shovelnose. Westhaven has completed 28,400 metres of diamond drilling to date in 2021. An additional 16 holes are in the lab pending assays. Wildfire Update: As of Friday September 3rd, the Evacuation Order issued by the Thompson-Nicola Regional District Operations Centre in Kamloops has been downgraded to an Evacuation Alert. Field crews and drill contractors are mobilizing to site and drilling will resume shortly. Once again, special thanks to the firefighters and first responders who put their lives at risk. Recent Drilling Highlights: SNR21-20; 265.00 metres of 0.49 g/t gold and 1.84 g/t silver, including 65.28m of 1.18 g/t Au and 3.37 g/t Ag, including 2.00m of 7.30 g/t Au and 10.23 g/t Ag, including 26.00m of 1.76 g/t Au and 4.00 g/t Ag, including 0.80m of 15.85 g/t Au and 8.99 g/t Ag. SNR21-27: 118.00m of 0.71 g/t Au and 2.12 g/t Ag,including 32.00m of 1.88 g/t Au and 4.95 g/t Ag, including 0.34m of 17.75 g/t Au and 22.40 g/t Ag, including 1.00m of 13.95 g/t Au and 7.49 g/t Ag. SNR21-29: 97.57m of 0.43 g/t Au and 1.88 g/t Ag, including 7.00m of 3.26 g/t Au and 7.63 g/t Ag, and 52.00m of 0.61 g/t Au and 1.33 g/t Ag, including 8.00m of 1.93 g/t Au and 3.49 g/t Ag. SNR21-30: 39.23m of 1.42 g/t Au and 9.80 g/t Ag, including 22.71m of 2.25 g/t Au and 15.53 g/t Ag, including 3.32m of 5.92g/t Au and 23.74 g/t Ag. As a significant portion of the resource drilling has been completed at South Zone, the drill program is now focused on follow-up testing of stronger quartz veining seen in holes SNR21-37 to SNR21-40 in Vein Zone 1 in the northwestern portion of South Zone. Drilling will also take place northward towards the Lear target for infill and step-out drilling on Vein Zone 3. The FMN target remains a priority for follow-up drilling. Drilling will resume at FMN upon completion of the resource drilling at South Zone where the shallower portions of the mineralized horizon in Vein Zone 1 will be targeted at the 1200-1300m level. This will be following up the last hole drilled at FMN, hole SN21-175, which encountered quartz-adularia veins contained in three subintervals of Vein Zone 1 spanning 246m downhole. Several CSAMT targets lying west of South Zone will be tested this fall as well. Drilling at Franz tested for the northwestern continuation of Vein Zone 1. Hole SN21-170 intersected a section of rhyolite hosted hydrothermal breccia that returned 0.16 g/t Au, 0.20 g/t Ag and 135 ppm arsenic over 1.63m. This intersection has extended Vein Zone 1 to the northwest by an additional 90 metres from where it was intersected in hole SN20-124. Gold mineralization was also encountered at the top of hole SN21-170 in a second northwest striking zone of chalcedony veining hosted in rhyolite, lying about 100m southwest of Vein Zone 1. This zone was first identified in hole SN20-123, which returned 0.204 g/t Au, 0.345 g/t Ag and 311 ppm arsenic over 16.79m. Hole SN21-170 returned 3.0m of 0.52 g/t Au. This zone has now been traced for 350m and remains open to the northwest.

07:42 EDT CarLotz announces first hub in Alabama - CarLotz announced it will open its first hub in Alabama. The hub, located at 3016 Government Blvd in Mobile, is expected to open later this year. "We are thrilled to announce our entry into the great state of Alabama," said Michael Bor, Cofounder and CEO of CarLotz. "With our first Georgia hub opening later this month, we are ramping up our growth in the Southeast and look forward to welcoming guests to our new hubs where they will have easy access to the exceptional service, real value and diverse inventory CarLotz provides."

07:40 EDT Canadian Solar signs O&M agreements with two PV plus battery storage projects - Canadian Solar (CSIQ) announced that it has signed long-term Operations & Maintenance, or O&M, agreements with two solar PV plus battery storage projects in the U.S., namely, the Slate and Mustang projects which were both developed by Canadian Solar's subsidiary Recurrent Energy and are currently owned by Goldman Sachs Asset Management Renewable Power (GS). The agreements cover the full Slate Project, which is a 300 MWac solar plant designed with a 140 MW / 561 MWh battery energy storage system; and the storage component of the Mustang Project, which is a 100 MWac solar plant retrofitted with a 75 MW / 300 MWh battery storage system. Both projects are located in Kings County, California. Under the long-term agreements, Canadian Solar will be responsible for various O&M obligations across both projects, including plant monitoring, NERC registration, performance management and preventative and corrective maintenance. Canadian Solar services will help to increase site availability, minimize downtime and maximize the value of the projects. Dr. Shawn Qu, Chairman and CEO of Canadian Solar said, "As we expand our market leadership position from solar energy into battery storage project development and systems integration, offering operations and maintenance services in battery storage is a natural extension of Canadian Solar's value proposition. We will continue to add value to our customers by providing the best quality service, maximize production of clean renewable energy and enhance the value of solar and battery storage assets through our O&M services. We are delighted to be selected by Goldman Sachs to provide O&M services to both the Mustang and Slate solar and storage projects and look forward to the long-term partnership."

07:39 EDT Digihost Technology produces 44.07 BTC during August - Digihost Technology provides unaudited Bitcoin production updates for August 2021. Corporate Highlights for August 31, 2021: Produced 44.07 BTC during the month, increasing total holdings to 446.2 BTC representing a fair market value of approximately $21.0 million as at August 31, 2021. Total Ethereum holdings of 563.89 ETH representing a fair market value of approximately $1.9 million as at August 31, 2021. Total digital asset inventory value consisting of BTC and ETH of approximately $22.9 million at the end of August. Cash on hand at August 31st was approximately $18.9 million, and total cash and digital asset holdings was approximately $41.7 million. Year-to-date deposits on equipment and infrastructure to be completed in Q4 2021 pertaining to the Company's core business of approximately $24.1 million. For the eight-month period ended August 31, 2021, the Company's mining fleet produced 310.58 BTC, with production broken down as follows: Quarter 1, 2021: 105.26 BTC; January: 33.70; February: 35.02; March: 36.54. Quarter 2, 2021: 109.97 BTC; April: 37.52; May: 34.26; June: 38.19. Quarter 3, 2021: 95.35 BTC; July: 51.28; August: 44.07 The Company mined approximately 23.57 more BTC in the first two months of Q3 2021 compared to the first two months of the previous quarter, representing an increase of 33%. Based on the BTC prices in these respective quarters and the increase in production of BTC mined, the fair market value of the Company's BTC mined on a quarter over quarter basis increased by approximately $821k. Compared to August of 2020, the Company mined approximately 28.58 more BTC in August of 2021, representing an increase of 185%. Based on August 31, 2021, BTC prices compared to August 31, 2020, and the increase in production of BTC mined, the fair market value of the Company's BTC mined in August 2021 increased by approximately $1.9 million.

07:37 EDT Cboe, EuroCCP debut new European derivatives market - Cboe Europe, the pan-European exchange operator and subsidiary of Cboe Global Markets, announced the successful launch of Cboe Europe Derivatives, or CEDX, a new Amsterdam-based futures and options marketplace. CEDX opened for trading on Monday 6 September, offering futures and options based on Cboe Europe single country and pan-European indices, and successfully executed and cleared its first trades. Contracts traded on CEDX are cleared at EuroCCP, Cboe's pan-European clearing house, allowing customers to benefit from efficiencies in trading and clearing. Ade Cordell, president of Cboe NL, said: "We are delighted to have successfully launched CEDX and are encouraged by the levels of customer interaction we've seen already. With the support of our launch participants, we have brought to life a brand-new exchange, clearing house and futures and options product suite. We couldn't be more excited for the future growth of this marketplace and Europe's equity derivatives market overall."

07:35 EDT Alexco Resource reports interim results from Bermingham Drilling - Alexco Resource reported initial results from its ongoing Bermingham Northeast Deep zone infill and extension drilling program in the Keno Hill Silver District, Yukon Territory. The current 19,000 meter drill program targets over 50 resource intercepts along a zone that was discovered in 2019 and extended over a 500 m strike length in 2020. 2021 Exploration Results Highlights. The 2021 exploration drilling program is currently approximately 80% complete with assays available from the first 24 holes. The drilling program is focused at depth northeast of the Bermingham deposit that contains silver mineral resources of 32.96 million ounces Indicated and 11.74 Moz Inferred. Interim results confirm the presence of an approximate 500 m long sub horizontal mineralized zone with at least a 100 m vertical extent located approximately 150 m below the Bermingham Northeast mining reserve. To achieve an accurate intersection pattern at depth, directional core drilling is being used to ensure a resource estimation can be completed as planned in Q4 2021. Alexco's Chairman and CEO, Clynt Nauman commented, "We are very encouraged by the initial results from the Bermingham Northeast Deep drilling, confirming the importance of this discovery both from an exploration and potentially, from an operations perspective. This zone of mineralization is shaping up to be within 200 meters of our currently planned underground ramp and haulage infrastructure. Upon completing an updated Mineral Resource Estimate for Bermingham in Q4, we will look to incorporate these results into an updated and expanded Mineral Reserve. The discovery also has significant implications in a district where historically, silver mineralization was considered shallow and discontinuous. The Bermingham mineralized corridor - shallow and deep - is still open both to the southwest to and beyond the Brefalt Fault offset, and to the northeast toward the adjacent historical Hector-Calumet mine."

07:30 EDT Adaptimmune trading resumes

07:28 EDT Northern Vertex provides Hercules Gold Project exploration update - Northern Vertex Mining provides an update on its 100 square kilometer Hercules Gold Project in western Nevada. Integration of recent and historic surface mapping, sampling, drilling, and property-scale geophysical survey data has resulted in the generation of four new verified gold target areas on the property, as well as indicated the potential for links between existing targets. Northern Vertex President, Michael G. Allen commented "We continue to advance the Hercules Project using both traditional and innovative exploration techniques. The results that we have received continue to show that the Hercules Gold Project has the potential to be a significant new discovery in Nevada, and we look forward to drilling on new and expanded targets on the Project." Key Points: Four new exploration target areas, Ursa, Como Ridge, Hades, and Jurassic Park have been identified; A sample from the eastern parts of the Hercules exploration target area returned 72.40 g/t gold and 2,690 g/t silver; Ongoing surface exploration continues to identify and further delineate structure-hosted epithermal precious metal mineralization in multiple areas; Results obtained from sagebrush phytogeochemical line sampling conducted over target areas in the north of the property indicate that they may be linked into one large mineralized system; Notice of Intent permits have been received for drilling the Sirens and Como-Comets target areas; Exploration target area prioritization is ongoing ahead of the anticipated Q3/2021 receipt of an Exploration Area Plan-of-Operations permit; Exploration drilling is planned for Q4/2021

07:26 EDT Osisko Mining announces results from drill program at Windfall project - Osisko Mining is pleased to provide new analytical results from the ongoing drill program at its 100% owned Windfall gold project located in the Abitibi greenstone belt, Urban Township, Eeyou Istchee James Bay, Quebec. Significant new analytical results presented below include 142 intercepts in 32 drill holes and 24 wedges. The infill intercepts are located inside defined February 2021 mineral resource estimate blocks. The expansion intercepts are located outside the February 2021 MRE blocks and either expand resource wireframes or are in a defined zone or corridor but do not yet correlate to a specific wireframe. Selected high-grade intercepts include: 512 g/t Au over 2.4 metres in WST-21-0833; 212 g/t Au over 2.4 metres in WST-21-0842; 86.8 g/t Au over 3.4 metres in OSK-W-21-2287-W4; 141 g/t Au over 2.0 metres and 29.0 g/t Au over 5.5 metres in OSK-W-21-2503-W4; 108 g/t Au over 2.3 metres in OSK-W-21-2531-W1; 42.1 g/t Au over 4.8 metres in OSK-W-21-2470; 17.3 g/t Au over 11.4 metres in OSK-W-21-2537-W1; 83.0 g/t Au over 2.0 metres in OSK-W-21-2548-W2, and 57.6 g/t Au over 2.1 metres in WST-21-0854A.

07:23 EDT Electric Last Mile Solutions completes structural confirmation impact testing - Electric Last Mile Solutions announced that it completed structural confirmation impact testing for its Urban Delivery commercial class 1 vehicle. With this phase complete, the body design has been frozen. Testing took place at the NHTSA validated Calspan facility in Buffalo, NY. ELMS plans to launch introduction models of the Urban Delivery electric vehicle in the U.S. market beginning late in the third quarter. Production will occur at the Company's plant in Mishawaka, Indiana.

07:23 EDT Points International announces TSX approval of share repurchase - Points International announced that the Toronto Stock Exchange has accepted its notice of intention to make a normal course issuer bid to repurchase up to 746,992 of its common shares, representing approximately 5% of its 14,939,842 common shares issued and outstanding as of August 31, 2021. Points has entered into an automatic share purchase plan with a broker in order to facilitate the Repurchase. The primary purpose of the Repurchase is purchases for cancellation. Under the automatic share purchase plan, Points' broker may repurchase shares at times when Points would ordinarily not be permitted to due to regulatory restrictions or self-imposed blackout periods. Repurchases will be made from time-to-time at the broker's discretion based upon parameters prescribed by the parties' written agreement. Repurchases may be effected through the facilities of the TSX, the NASDAQ Capital Market or other alternative trading systems in the United States and Canada. All purchases of common shares will be made in accordance with applicable securities laws and stock exchange rules of the United States and Canada. Repurchases on NASDAQ will be at the market price at the time of purchase in compliance with applicable securities laws of the United States and Repurchases on the TSX will be at the market price at the time of purchase in accordance with the rules and policies of the TSX. Purchases may also be made through other alternative trading systems in the United States and Canada, or by such other means as may be permitted by the TSX, NASDAQ and applicable law. As a result of certain rules and policies of the TSX, subject to certain permitted exceptions, the maximum number of shares which can be repurchased per day on the TSX is 1,070 based on 25% of the average daily trading volume on the TSX for the prior six months Subject to regulatory requirements, the actual number of common shares purchased and the timing of such purchases, if any, will be determined by Points' broker having regard to future price movements and other factors, including the parameters prescribed by the parties' written agreement. The Repurchase will commence on September 9, 2021 and will terminate on September 8, 2022. Points did not purchase any common shares under its previous normal course issuer bid. Points' previous normal course issuer bid commenced on September 9, 2020 and will terminate on September 8, 2021.

07:21 EDT Flora Growth gets commercial export quota of cannabis flower from Colombian govt - Flora Growth is pleased to announce that it has received its 2021 export quota from the Colombian Technical Quotas Group, TQG, to cultivate up to 7,900 kilograms of high-THC cannabis dried flower for direct sale or processing into derivative products for export to international markets. "We have been eagerly anticipating and preparing for this announcement by cloning thousands of plants which we currently have in propagation waiting to be transferred into our fields. While awaiting this quota, we were focused on optimizing our cultivation strategy and demonstrating our industry-leading production costs of just US$0.06 per gram, while continuing to build out our facilities and applying for third party certifications," said Javier Franco, VP of Agriculture of Flora. "While we prioritize planting the new high-THC cultivars, it's also important to note we are actively harvesting our high-CBD crops, and anticipate that this harvest will create a robust pipeline of cannabis derivatives for Flora to use across its premium brands and products, as well as for export to multiple international markets." Management believes that the new 2021 export quota allocation that Flora has been provided to cultivate, process, and distribute high-THC cannabis dried flower and derivatives, will be sufficient to meet the international demand for Flora's product for the remainder of 2021 and at the onset of 2022. Flora previously announced agreements with Kiricann and Evergreen Pharmacare to supply dried flower and derivatives for distribution in Africa and the EU, as well as to Australia, respectively. Additionally, the Company announced that it intends to make a strategic investment into Hoshi International, which will establish Flora as a preferred supplier to Hoshi's two EU processing facilities, located in Malta and Portugal. "This is a significant milestone for the Company and represents a major opportunity to export our high-margin, high-THC goods to legal markets around the world," said Jason Warnock, Chief Revenue Officer of Flora. "It's also important to note that this quota is for THC cannabis products as Flora does not require any quota for non-psychoactive cannabis flower or derivatives."

07:20 EDT Adaptimmune, Genentech enter collaboration for allogeneic T-cell therapies - Adaptimmune Therapeutics (ADAP) announced that it has entered into a strategic collaboration and license agreement with Genentech, a member of the Roche Group (RHHBY) to develop and commercialize allogeneic cell therapies to treat multiple oncology indications. The collaboration has two components: Development of allogeneic T-cell therapies for up to five shared cancer targets; Development of personalized allogeneic T-cell therapies. For each component, Adaptimmune will be responsible for developing clinical candidates using its induced pluripotent stem cell derived allogeneic platform to produce T-cells. Genentech will be responsible for the input TCRs and subsequent clinical development and commercialization. Under the terms of the agreement, Adaptimmune will receive an upfront payment of $150 million and additional payments of $150 million over five years, unless the agreement is earlier terminated. In addition, Adaptimmune may be eligible to receive research, development, regulatory and commercial milestones payments potentially exceeding $3 billion in aggregate value. Adaptimmune will also receive tiered royalties on net sales in the mid-single to low-double digits. Adaptimmune has the right to opt in to a 50/50 U.S. profit/cost share on "off-the-shelf" products. If Adaptimmune elects to opt in, then Adaptimmune will be eligible to share 50 percent of profits and losses from U.S. sales on such products and is eligible to receive ex-U.S. regulatory and sales-based milestone payments, as well as royalties on ex-U.S. net sales. The effectiveness of the agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

07:18 EDT GXO Logistics pilotes customised robotic arm for fashion ecommerce logistics - GXO Logistics has launched an pilot of intelligent automation at its fashion ecommerce warehouse in Tilburg, the Netherlands. GXO's pilot of the Pick-it-Easy Robot station is tailored for one of its key global customers, in collaboration with value chain tech provider KNAPP AG. The pilot is the first application of KNAPP's Pick-it-Easy Robot technology for automated pocket induction in the sector for apparel logistics. The Pick-it-Easy's Artificial Intelligence based vision system recognizes each product and identifies the optimal gripping point and gripping speed, while the arm places items into a pocket conveyor for sorting, grouping and routing to packing stations. It addresses the unique logistics challenges presented by the apparel industry, given the vast range of product sizes, shapes, textures, weights and packaging. After the implementation of the first KNAPP Pick-it-Easy Robot is complete, GXO plans to expand its use of technology in Tilburg with an additional four robots.

07:17 EDT Shutterstock acquires PicMonkey, online graphic design platform - Shutterstock announced the acquisition of PicMonkey, an online graphic design and image editing platform. "Content is at the core of Shutterstock's offering, and selecting an asset is just one step of the creative process. A key element of Shutterstock's strategy and vision is providing a suite of solutions for the entire creative journey, regardless of experience or expertise level," said Stan Pavlovsky, Chief Executive Officer at Shutterstock. "PicMonkey's easy-to-use design and editing tools, collaboration features across teams, and robust library of pre-designed templates makes professional publishing assets accessible at scale to anyone, and is expected to allow Shutterstock to enhance and accelerate the delivery of our vision for our customers around the world." Key features of the PicMonkey tool includes photo editing, effects, touch-up tools, brand kits, cloud storage video, animations, and multi-page for creators, solopreneurs, social marketers, marketing professionals, pro designers and casual creatives. "These design and editing features represent a natural extension of Shutterstock's content offering, and on a combined basis, will enable the delivery of a more unified customer experience across the creation journey," the company said.

07:16 EDT Mimecast appoints Joe Mercurio as interim CRO - Mimecast announced it has appointed Joe Mercurio Interim Chief Revenue Officer, effective October 5, 2021. This appointment follows the resignation of Chief Revenue Officer, Dino DiMarino, who will depart from the Company in early October to pursue another opportunity. Mr. DiMarino will work with Mr. Mercurio, supported by CEO Peter Bauer, CFO Rafe Brown as well as the existing global sales leadership team, to facilitate an orderly transition. Mimecast has initiated a search to identify Mr. DiMarino's successor with the assistance of the executive search firm Daversa Partners. Mercurio has been with Mimecast for more than four years, most recently as the Senior Vice President of Sales, North America.

07:16 EDT Lexaria Bioscience reports initial results from HYPER-H21-2 study - Lexaria Bioscience reported initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH-processed cannabidiol, or CBD, for potential application against hypertension. Partial results related to blood pressure are being released, while additional BP subset analyses, sleep quality and all other data analyses are in progress and will be reported upon when complete. At selected times during the 24-hour study, volunteers with mild to moderate hypertension averaged as much as a 20 mmHg, or 23%, decrease in blood pressure relative to placebo. Over the 24-hour ambulatory monitoring period, volunteers averaged a significant reduction of 7% in systolic pressure with DehydraTECH-CBD relative to placebo. Over the 24-hour ambulatory monitoring period, volunteers averaged a significant reduction of 5.3% in MAP with DehydraTECH-CBD relative to placebo. Over the 24-hour ambulatory monitoring period, volunteers averaged a significant reduction of 3.5% in diastolic pressure relative to an increase in diastolic pressure from baseline with DehydraTECH-CBD relative to placebo. DehydraTECH-CBD triggered its most significant effects upon BP attenuation through the overnight period while subjects slept and in the early morning period. This observation could have tremendous value therapeutically as these periods of the day are most often associated with cardiac stress and infarct events in hypertensive patients when people rise suddenly from and/or become increasingly active relative to the supine/sleeping state. Analysis of the physical activity levels of the volunteers with mild to moderate hypertension during the 24-hour monitored period showed no significant differences in activity between the placebo and the DehydraTECH-CBD treated volunteers, indicating that the observed differences in BP were not due to disparate physical movement or demands. DehydraTECH-CBD was well tolerated by all subjects, with no serious adverse events or side effects observed or reported or incidence differences between groups.

07:14 EDT Enbridge enters definitive purchase agreement to acquire Moda Midstream for $3B - Enbridge announced that it has entered into a definitive purchase agreement with EnCap Flatrock Midstream to acquire Moda Midstream Operating for $3B in cash, subject to closing adjustments. The acquisition will advance the company's U.S. Gulf Coast export strategy. "We're very excited about acquiring North America's premium, very large crude carrier capable, crude export terminal," commented Al Monaco, President and Chief Executive Officer of Enbridge. "Over the last several years we've been building a strong position in the U.S. Gulf Coast through both natural gas and crude infrastructure. Our strategy is driven by the important role that low cost, sustainable North America energy supply will play in meeting growing global demand. With close proximity to world-class Permian reserves, and with cost effective and efficient export infrastructure, our new Enbridge Ingleside terminal will be critical to capitalizing on North America's energy advantage. Central to the transaction, Enbridge will acquire a 100% operating interest in the Ingleside Energy Center, located near Corpus Christi, Texas. Enbridge will also acquire a 20% interest in the 670-thousand-barrel per day Cactus II Pipeline, a 100% operating interest in the 300-thousand-barrel per day Viola pipeline, and a 100% operating interest in the 350-thousand-barrel Taft Terminal. The transaction is expected to close in the fourth quarter of 2021, subject to customary regulatory approvals and closing conditions. Moda's Ingleside Management and key Moda marine terminal personnel will remain in place following closing of the transaction, ensuring continuity of operations and ongoing development activities.

07:12 EDT FAA approves G-1 certiication basis for Archer - Archer Aviation has been actively engaged with the FAA through its Center for Emerging Concepts & Innovation and the Los Angeles Aircraft Certification Office to develop the airworthiness and environmental requirements necessary for full certification of its eVTOL aircraft. Archer is pleased to announce that the FAA G-1 Issue Paper: Certification Basis has been approved and signed, enabling Archer to move further down the runway towards its goal of obtaining an FAA Type Certification for its eVTOL aircraft. The G-1 Certification Basis is based on the FAA's certification standards contained in 14 C.F.R. Part 23. With Part 23 as the foundation, the G-1 Certification Basis sets forth the specific Airworthiness Standards and Environmental Standards required for FAA Type Certification. With these requirements now established, Archer can focus on finalizing its G-2 Issue Paper with the FAA, which will set forth the means of compliance to meet the requirements set forth in the G-1 Issue Paper. Archer has been working on the means of compliance for the G-2 Issue Paper with the FAA since earlier this year, as well as the necessary testing and methods required to demonstrate safety and compliance of our aircraft.

07:11 EDT Protagonist Therapeutics appoints Scott Plevy as Executive VP, Therapeutic Head - Protagonist Therapeutics announced the appointment of Scott Plevy, M.D., to the role of Executive Vice President, or VP, and Therapeutic Head, Gastroenterology. Dr. Plevy will oversee clinical operations and development of Protagonist's ongoing and future programs in gastrointestinal diseases, including PN-943, an investigational drug candidate currently in a Phase 2 study in ulcerative colitis. Dr. Plevy is a gastroenterologist and molecular immunologist who most recently served as Chief Scientific Officer at Senda Biosciences.

07:10 EDT Main Street announces follow-on investments - Main Street Capital announces that it recently invested a total of $26M in first lien, senior secured term debt in two existing portfolio companies. Main Street recently completed a follow-on investment in OMi Holdings to support a recapitalization of OMi. Main Street's first investment in OMi was completed in April 2008. Main Street also recently completed a follow-on investment in Cody Pools.

07:09 EDT Alnylam gives more data on HELIOS-A Phase 3 study of vutrisiran for amyloidosis - Alnylam Pharmaceuticals announced additional positive results from subgroup analyses and exploratory endpoints of the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated amyloidosis. Data presented at the 3rd European ATTR Amyloidosis Meeting further supports and builds on the previously reported primary and secondary endpoint results of the HELIOS-A study in hereditary ATTR amyloidosis patients with polyneuropathy, with improvements observed across important areas of patient health and function, including neuropathy impairment, Quality of Life , ability to perform daily activities and social engagement, nutritional status, and cardiac stress. "Hereditary ATTR amyloidosis is a multisystem, rapidly progressive disease with significant impact on the daily lives of patients, and which worsens over time without appropriate management," said Pushkal Garg, M.D., Chief Medical Officer of Alnylam. "These additional data from the HELIOS-A study show the potential of vutrisiran in treating a broad group of patients with hATTR amyloidosis with polyneuropathy, with encouraging improvements seen across a range of important health and functional measures. Additionally, patients experienced improvements in neuropathy impairment and quality of life scores regardless of prior TTR stabilizer use. We look forward to sharing additional results at the 18-month readout, expected later this year. With the recent NDA submission accepted for review by the U.S. FDA and planned regulatory submission in Europe ahead of schedule, we are continuing our progress to bring vutrisiran forward as a potential new treatment option for hATTR amyloidosis patients with polyneuropathy, with subcutaneous administration and quarterly dosing." The U.S. Food and Drug Administration recently accepted the New Drug Application submission for review for vutrisiran and has set an action date of April 14, 2022 under the Prescription Drug User Fee Act . Additionally, it was recently announced that based on discussions with the European Medicines Agency the Company now plans to file, ahead of schedule, a Marketing Authorization Application for vutrisiran based on 9-month results from the HELIOS-A study.

07:08 EDT Tantu, Ginkgo Bioworks announce partnership to accelerate research, development - Tantu and Ginkgo Bioworks announced a partnership to accelerate the research and development of Tantu's therapeutic genes. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition, serves customers across industries seeking to develop new products using biology. Tantu is working to create an orally administered, living biotherapeutic that will produce and apply anti-inflammatory therapeutic proteins directly into diseased sites in the gut, resulting in improved gut barrier function and faster mucosal healing in patients. "We are excited to partner with a pre-seed company like Tantu with the goal of reducing their time-to-market because we view it as an opportunity to invest in the biotech industry through the startups that are driving forward so much innovation," said Jason Kelly, CEO and co-founder of Ginkgo Bioworks. "Working with Tantu provides Ginkgo with the opportunity to leverage its expertise in pharmaceuticals to support the development of a potentially transformative therapeutic for the millions struggling with digestive disorders."

07:07 EDT Western Asset Mortgage CEO Jennifer Murphy to resign, Jennifer Murphy to succeed - Western Asset Mortgage announced that Jennifer Murphy will resign from her positions as president, CEO and as a member of the board of directors of the company, effective October 1, to pursue a new venture. To replace her, the board of directors of the company has appointed Bonnie Wongtrakool as CEO, and Lisa Meyer as president of the company, effective October 1. Wongtrakool will also be appointed to the board. Meyer will continue to serve as CFO of the company. Both Wongtrakool and Meyer will work closely with Murphy, who will remain with the company as a senior advisor through December 31 to ensure a transition of leadership. Wongtrakool joined Western Asset in 2003 and has over 22 years of investment industry experience.

07:04 EDT Repare Therapeutics appoints Thomas Civik as chairman - Repare Therapeutics announced the appointment of Thomas Civik to its board of directors and as its chairman. He replaces Jerel Davis, managing director at Versant Ventures, who will remain a member of the company's board. Tom Civik most recently served as president and CEO of Five Prime Therapeutics until its acquisition by Amgen for $1.9B in April.

07:02 EDT Immunome reports antibody cocktail demonstrates activity against COVID variants - Immunome announced that its three-antibody cocktail has demonstrated potent neutralizing activity against SARS-CoV-2 Lambda and Delta AY.1/2 variants, in pre-clinical testing conducted by Immunome on lentiviral-based pseudovirus. IMM-BCP-01 consists of three antibodies that bind to non-overlapping regions of the spike protein and show combinatorial activity against multiple strains of SARS-CoV-2.

07:00 EDT Adaptimmune trading halted, news dissemination

06:56 EDT VF Corp. director Veronica Wu steps down - VF Corporation announced that Veronica Wu has informed VF of her decision to step down from the company's Board of Directors, effective immediately. Ms. Wu's decision to step down from the Board was not the result of any disagreement with VF on any matter relating to VF's operations, policies or practices. Wu was appointed to the VF Board of Directors in March of 2019. In connection with Wu's stepping down, the size of the VF Board will be reduced from 12 members to 11 members until a new director is identified.

06:53 EDT Probe Metals announces positive PEA for Val-d'OR East Project - Probe Metals is pleased to announce positive results from the independent Preliminary Economic Assessment for its 100% owned Val-d'Or East project located near Val-d'Or, Quebec. The PEA provides a base case assessment of developing the Val-d'Or East mineral resource by open pit and underground mining, and gold recovery with a standard free milling flowsheet, incorporating gravity and leaching of the gravity tails, with 50% estimated to be recovered via gravity. The economic model supports an operation with low capital cost and high rate of return over a 12.5-year mine life, with significant average annual production of 207,000 ounces. The PEA was prepared by Ausenco Engineering Canada in accordance with National Instrument 43-101 - Standards of Disclosure for Mineral Projects. The Val-d'Or East Project includes the properties on the Pascalis Gold Trend, the Monique Gold Trend, the Courvan Gold Trend and the Lapaska property, which are all 100% owned by Probe. The Project benefits from world-class mining infrastructure, expertise for underground and open-pit operations and highly qualified personnel. It can be easily reached by roads that are well maintained in all seasons. Several large-scale mining operations and gold mills are currently active in the area. Since 1930, approximately 30 million ounces of gold have been produced at Val-d'Or. Since 2016, Probe has been consolidating its land position in the highly prospective Val-d'Or East area in the province of Quebec. The Val-d'Or East Project is a district-scale land package comprising 436 square kilometres and represents one of the largest consolidated land holdings in the Val-d'Or mining camp. The current total resource stands at 1,800,900 ounces of gold in the Measured and Indicated category and 2,309,600 ounces of gold in the Inferred category. Ausenco was appointed as lead consultant in November of 2020 to prepare the PEA in accordance with NI 43-101, and was assisted by Moose Mountain Technical Services for the mine design. The economic analysis was performed assuming a 5% discount rate. On a pre-tax basis, the NPV5% is $991 million, the IRR is 47.2% and the payback period is 1.8 years. On an After-Tax basis, the NPV5% is $598 million, the IRR is 32.8% and the payback period is 2.7 years.

06:49 EDT Merck's KEYTRUDA approved in China in combination with chemotherapy - Merck has been approved by the National Medical Products Administration in China in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus or gastroesophageal junction. This new indication was granted approval based on overall survival findings from the pivotal Phase 3 KEYNOTE-590 trial. KEYTRUDA is now approved for eight indications across five different types of cancer in China. In the global KEYNOTE-590 study, KEYTRUDA in combination with chemotherapy demonstrated statistically significant improvements in OS and progression-free survival compared with 5-FU and cisplatin alone. KEYTRUDA plus 5-FU and cisplatin reduced the risk of death by 27%. The median OS was 12.4 months for patients treated with KEYTRUDA plus 5-FU and cisplatin and 9.8 months for patients treated with 5-FU and cisplatin alone. KEYTRUDA plus 5-FU and cisplatin reduced the risk of disease progression or death by 35%. The median PFS was 6.3 months for patients treated with KEYTRUDA plus 5-FU and cisplatin and 5.8 months for patients treated with 5-FU and cisplatin alone in all randomized patients. The Chinese package insert notes that the safety of KEYTRUDA plus chemotherapy was investigated in 51 Chinese patients with esophageal carcinoma in KEYNOTE-590, and the safety profile of the Chinese patients was generally consistent with the known safety profiles of KEYTRUDA monotherapy and chemotherapy.

06:42 EDT eGain launches Knowledge Hub management solution - eGain announced the availability of eGain Knowledge Hub, the company's next-gen knowledge management solution. The company said, "Powered by AI reasoning, ML, Natural Language Processing, and analytics, eGain Knowledge Hub is a rich, one-stop knowledge management solution for the digital-first, remote-first era. Among the benefits are: Knowledge harmony created by centralizing 360 customer context, omnichannel content, profiled access, personalization, search methods, conversational guidance, and analytic insight into one platform; Assured customer service and agent confidence with the single right answer to customer questions; Consistency and process compliance at scale across touchpoints; Rich functionality out of the box for quick business value-say goodbye to multi-year development, customization, and integration projects with toolkits; Easy governance, insights, and optimization."

06:38 EDT Trilogy Metals provides update on Upper Kobuk Mineral projects in Alaska - Trilogy Metals provided an update on the summer field activities currently being managed by Ambler Metals, the joint venture operating company equally owned by Trilogy and South32 at the Upper Kobuk Mineral Projects located in Northwestern Alaska. The exploration camp opened in May in preparation for the start-up of drilling in June at the Arctic Project. The drilling contractor deployed three diamond drill rigs in June to focus on a total of 7,600 meters of planned drilling at Arctic with most of the drilling targeting infill areas to improve the confidence of the Mineral Resources, and geotechnical and metallurgical drill holes to further de-risk the project. An additional 7,000 meters of exploration drilling was planned at targets near the Arctic deposit and elsewhere in the Ambler Mining District. Drilling productivity at the project is behind schedule due to adverse weather conditions in the district and challenges in fully staffing the exploration program. As a result, Ambler Metals is unlikely to achieve the drill meters planned at Arctic for this field season. Notwithstanding, the lower-than-expected drilling productivity, Ambler Metals has recovered sufficient mineralized material to complete the planned metallurgical program at Arctic. Also, all the planned geotechnical drilling was completed at the Arctic Project. The Company does not expect the shortfall in the drilling program to influence the permitting and development timeline of the Arctic Project. In consultation with joint-venture owners Trilogy and South32, Ambler Metals will keep the camp open longer than originally planned to complete as much of the regional drilling program as possible. Timing of camp closure this season will be weather dependent. In response to the slower drilling this season, Ambler Metals has also redeployed some of the geological staff at site to focus on regional mapping and soil sampling around satellite deposits near the Arctic Project and at the Bornite Project. Information gathered during this season will assist with future exploration activities including identifying drill targets for next year's field season.

06:35 EDT Avantor to acquire Masterflex business of Antylia Scientific for $2.9B - Avantor announced that it has entered into a definitive agreement to acquire the Masterflex bioprocessing business and related assets of Antylia Scientific, a privately held, portfolio company of investment firms GTCR and Golden Gate Capital. The all-cash transaction is valued at $2.9B, subject to final adjustments at closing. Given anticipated tax benefits from the transaction structure, the net purchase price is approximately $2.7B. Headquartered in Vernon Hills, Illinois, Masterflex is a global manufacturer of peristaltic pumps and aseptic single-use fluid transfer technologies with estimated 2022 revenues of approximately $300M. The transaction is expected to enhance Avantor's revenue growth and margin profile and be accretive to adjusted EPS in year one post-acquisition. Avantor has a full debt financing commitment for the transaction, and retains the flexibility to alternately obtain debt or equity financing in the market in order to achieve its targeted capital structure. The transaction is expected to be completed in Q4 and is subject to customary closing conditions, including receipt of applicable regulatory approvals.

06:34 EDT Energous, TAGnology partner for over-the-air wireless power solutions - Energous Corporation announced a partnership with TAGnology RFID. Under the arrangement, TAGnology will work as an industrial design house for Energous customers, helping to implement wireless power solutions, proofs of concept, and manage development projects. In addition, TAGnology delivers training and technical support in the region and will serve as a provider of Energous' wireless power solutions and developer kits in Europe through its ecommerce website and distribution channel.

06:32 EDT Gold Resource starts to bring back workers to Don David gold mine site - Gold Resource announced it has started to bring employees back to the Don David gold mine site over the past several days, each of whom were required to quarantine for three days and then tested for COVID-19. Of the 332 brought back, 329 tested negative for COVID-19 and were allowed to access the operations. The company is cautiously optimistic that the advice from its medical staff and an epidemiologist, to reduce the movement of people coming to the mine site from the local communities and the region, is meeting goals of minimizing the further spread of infection amongst our workforce and the local communities and lessening the extreme strain on our accommodations.

06:30 EDT Park Hotels & Resorts reports liquidity of $1.8B as of August 31 - The company said, "Following the sale of the Le Meridien San Francisco, the Company has just $78 million outstanding on its sole remaining corporate term loan. As of August 31, 2021, Park had estimated liquidity of approximately $1.8 billion, including estimated cash and cash equivalents of $769 million and $1.075 billion of available capacity remaining under the Company's revolving credit facility."

06:28 EDT Park Hotels expects fundamentals to be softer than expected through October - The company said, "Despite witnessing exceptionally strong results in July and August, the Company now anticipates fundamentals to be softer than expected through at least October as the spread of the Delta variant has tempered demand. Markets meaningfully impacted include Hawaii, San Francisco and Orlando with most of the attrition related to group cancellations. Despite the near-term weakness, however, demand trends for November and December remain steady, as group bookings and leisure demand continue to hold."

06:26 EDT State Street to acquire Brown Brothers Harriman Investor Services for $3.5B

06:22 EDT Fat Brands enters new 200+ development deal with Kitopi in the Middle East - FAT Brands is growing its footprint in the Middle East with 136 brick-and-mortar restaurant locations across five countries. In partnership with Kitopi, the master franchisee for this deal, six FAT Brands concepts will be opening over the next five years, including Fatburger, Johnny Rockets, Buffalo's Cafe, Great American Cookies, Elevation Burger, and Yalla Mediterranean. United Arab Emirates, Kingdom of Saudi Arabia, Bahrain, Qatar, and Kuwait are the locales of the FAT Brands expansion. While the 136 brick-and-mortar stores will open over the next five years, the FAT Brands concepts will become available within the next year through Kitopi's existing footprint of more than 70 managed cloud kitchens, otherwise referred to as ghost kitchens throughout the region. The Middle East has proven to be fruitful for FAT Brands, with their brands steadily opening new stores across various countries for over a decade.

06:18 EDT Natera enters MRD agreement with NRG Oncology - Natera announced an agreement with NRG Oncology, a National Cancer Institute, or NCI-funded group, to use the Signatera personalized molecular residual disease, or MRD, test in NRG-GI008: Colon Adjuvant Chemotherapy based on Evaluation of Residual Disease, a prospective, multi-center, randomized clinical trial to investigate MRD-guided treatment strategies for patients with early stage colon cancer. The study will enroll approximately 2,000 patients with stage II or III colon cancer after resection. Patients identified as MRD-negative by Signatera will be randomized to receive either standard-of-care, or SOC, adjuvant chemotherapy or observation unless circulating tumor DNA, or ctDNA, is subsequently detected during surveillance. Patients identified as MRD-positive will be randomized to receive SOC chemotherapy or an intensified regimen with mFOLFIRINOX. The study's primary endpoint is to compare disease-free survival in MRD-negative patients between immediate vs. delayed adjuvant chemotherapy, and MRD-positive patients between SOC vs. intensified adjuvant chemotherapy. The CIRCULATE-US study is part of an international collaboration announced at the ESMO 2019 conference to tailor adjuvant chemotherapy using emerging ctDNA technologies.

06:16 EDT Columbia Property to be acquired by funds managed by PIMCO in $3.9B deal

06:13 EDT United Therapeutics presents new Tyvaso DPI data at ERS - United Therapeutics presented new clinical data from the BREEZE study evaluating Tyvaso DPI in patients with pulmonary arterial hypertension, or PAH, at the European Respiratory Society, or ERS, International Congress. Top line data showing the BREEZE study met its primary objective were released in January. Secondary objectives of the study included changes in six-minute walk distance, or 6MWD, device preference and satisfaction as evaluated through the Preference Questionnaire for Inhaled Treprostinil Devices, or PQ-ITD, and patient reported PAH symptoms and impact, or PAH-SYMPACT. Three weeks after switching from Tyvaso to Tyvaso DPI, patients in the BREEZE study demonstrated: significant improvements in 6MWD compared to baseline. improvements of 11.5 meters in 6MWD compared to baseline were observed through the three-week treatment phase. Significant improvements in overall satisfaction with the Tyvaso DPI inhaler. Using the PQ-ITD, significant improvements were observed in overall satisfaction with the Tyvaso DPI inhaler. Significant improvements in PAH Impact. The SYMPACT questionnaire includes domains on physical impacts, cognitive/emotional impacts, cardiopulmonary symptoms, and cardiovascular symptoms. Significant improvements in PAH impacts were observed in physical impacts and cognitive/emotional impacts at week three. Subjects in BREEZE were given the opportunity to continue in an optional extension phase, or OEP. All subjects who completed the treatment phase elected to continue in the OEP. Improvements in 6MWD compared to baseline were sustained in the OEP through the data cut-off date.

06:10 EDT Dolby collaborates with Cinemo for Dolby Atmos music experience in cars - Dolby Laboratories and Cinemo announced a collaboration aimed at accelerating the integration of Dolby Atmos, into vehicles. Announced at IAA Mobility during Dolby's panel on how the immersive sound technology is set to drive a revolution for in car entertainment, the collaboration also means that Cinemo has become the very first middleware licensee globally of the Dolby Car Experience. By working with Cinemo, car makers will be able to access immersive audio, enabling automotive companies to provide a seamless, Dolby Atmos Music listening experience to vehicle owners.

06:07 EDT Matador announces upgrades to credit rating, senior unsecured nots - Matador Resources Company announced recent upgrades by Moody's Investors Service to the Company's corporate credit rating and senior unsecured notes. On September 1, 2021, Moody's upgraded Matador's Corporate Family Rating from B2 to B1 and upgraded Matador's senior unsecured notes from B3 to B2. Moody's also upgraded Matador's Speculative Grade Liquidity rating from SGL-3 to SGL-2 to reflect good liquidity.

06:06 EDT Tritium annnounces A$40M private placement financing by Cigna Investments - Tritium Holdings announced a A$40M private placement by Cigna Investments, the investment arm of Cigna Corporation (CI). Tritium intends to use the proceeds from the private placement to continue scaling its global operations, including production, sales and administrative support, during its ongoing business combination with Decarbonization Plus Acquisition Corporation II (DCRN), which was announced on May 26, 2021, in an effort to satisfy Tritium's existing order backlog from its customers. This is the second private placement financing by Cigna, following a June 2020 private placement of A$45M.

06:01 EDT Thompson Street Capital Partners acquires Vector Laboratories - Thompson Street Capital Partners announced it has acquired Vector Laboratories, the Protein Detection business unit of Maravai. Vector Laboratories is a manufacturer of labeling and visual detection reagents for life science researchers doing tissue-based protein detection and characterization. The acquisition of Vector adds to TSCP's experience in life sciences. Vector Laboratories provides consumable reagents used in slide staining and imaging workflows within life science research, allowing scientists to better locate and identify certain proteins within a tissue sample. Vector's primary end markets are academic research labs and corporations, provided either directly to customers or via distributors and resellers.

05:59 EDT Genius Sports enters multi-year sports data partnership with Caesars - Genius Sports (GENI) announced a new strategic relationship with Caesars (CZR). Caesars' portfolio of casinos, sportsbooks and wagering entities will have access to Genius Sports' entire official sports data content offering, including customer acquisition tools, and fan engagement solutions. Genius Sports data feeds will support the Caesars trading and sportsbook platform by providing access to official NFL products, including official live sports data feeds. In addition, Genius Sports will become a programmatic advertising partner to Caesars Entertainment and supply its latest marketing technology to drive customer acquisition, engagement and retention for Caesars' digital sportsbook and casino products. In April, Caesars Entertainment was selected as one of the NFL's official sports betting partners. As an extension of that partnership, Caesars and Genius Sports now have entered into a deal to further Caesars' official NFL-backed sportsbook offerings, by leveraging NFL official data, Next Gen Stats. Alongside NFL content exclusive to Genius Sports, Caesars Entertainment will gain access to official data-powered in-play content for other U.S. and global sports, including NASCAR, English Premier League, Argentinian and Colombian soccer, as well as Liga MX.

05:27 EDT Gol Linhas announces preliminary traffic figures for August - Gol Linhas announced preliminary air traffic figures for the month of August, compared to the same period in 2020. In the domestic market, demand for Gol's flights increased 85% and supply increased by 83%. Gol's domestic load factor was 80.2% in August, a 0.8 percentage point increase in comparison to August 2020. Gol transported 1.5M passengers during the month, a 87% increase over August 2020. Gol reduced its operations in the last 10 days of the month in order to migrate its passenger service system to Sabre Systems. Gol did not operate regular international flights during the month.

05:22 EDT NeuExcell Therapeutics, Spark Therapeutics enter gene therapy collaboration - NeuExcell Therapeutics and Spark Therapeutics, a member of Roche, announced a gene therapy collaboration aimed at developing a safe and effective treatment for patients suffering from Huntington's Disease, or HD. Under the terms of the agreement, Spark Therapeutics will receive access to NeuExcell's proprietary neuro-regenerative gene therapy platform and capabilities. NeuExcell's research team will collaborate closely with Spark Therapeutics to advance the program. Under the option license NeuExcell is eligible to receive upfront, license fees, R&D and Sales milestone payments up to approximately $190M plus product royalties. Under this agreement, Spark Therapeutics has the option to license the exclusive worldwide rights of the NeuExcell's HD program.

05:15 EDT Nokia, Infradata deploy interconnect solution for NorthC Datacenters - Nokia and Infradata announced an integrated IP/optical data center interconnect solution for NorthC Datacenters, the largest regional data center provider in the Netherlands. The solution creates a single virtual data center that connects 10 NorthC data centers. The high-speed Region Connect Ring enables NorthC to offer its customers data center interconnection and cloud connectivity. Nokia's integrated IP/optical solution combines 7750 Service Routers with 1830 Photonic Service Switches and network automation. The solution enables NorthC to improve its customers' data center connectivity speed and reliability by offering Layer 2 IP/MPLS interconnection services between its data centers to meet their bandwidth, latency, and performance needs.

05:06 EDT Accenture announces intent to acquire Benext, terms undisclosed - Accenture has announced its intent to acquire Benext, an independent product consulting company specializing in product management, agile coaching, cloud-based development and data science. Financial terms of the transaction are not being disclosed. Founded in 2014 and based in France, Benext is a full-stack, product consulting company experienced in helping clients design, organize, deploy, and manage their digital products. The company's approximately 160 professionals would join Octo Technology, already a part of Accenture since 2017. Octo Technology is a technology consultancy specializing in digital transformation and software development. The Octo team is primarily located in France and also operates across Belgium, the Netherlands and Luxembourg.

04:55 EDT SoftBank enters partnership, equity swap agreement with Deutsche Telekom - SoftBank Group (SFTBY) announced that it has entered into a strategic partnership and equity share swap agreement with Deutsche Telekom (DTEGY). Under the strategic partnership between the two companies, SoftBank's more than 300 portfolio companies gain access to an additional, approximately 240M DT customers across Europe and the U.S., providing these portfolio companies the ability to scale quickly and at a low cost." Under the equity share swap agreement, DT will exercise a portion of its call options that were granted by SoftBank in connection with their June 2020 agreement. DT will acquire approximately 45M T-Mobile US (TMUS) shares from SoftBank in exchange for issuing 225M new DT shares to SoftBank from its authorized capital. In a subsequent step, DT envisages exercising call options to acquire another approximately 20M TMUS shares from SoftBank by re-investing $2.4B of expected disposal proceeds from the announced sale of T-Mobile Netherlands. As a result of these transactions - the equity share swap and the re-investment of proceeds - SoftBank will become a 4.5% shareholder in DT and retain a 3.3% equity stake in T-Mobile US, which could increase to 6.9% through True-Up Shares, if T-Mobile US stock price were to hit certain milestones. "The transaction is financially compelling. SoftBank is exchanging TMUS shares underlying primarily fixed price options with no upside, for stock in DT, which SoftBank believes has significant long-term upside beyond the agreed reference price of EUR 20. SoftBank will become the second largest private shareholder with intended board representation. In addition, SoftBank retains meaningful exposure to TMUS through shares underlying primarily floating options and, potentially, True-up Shares2. SoftBank expects significant ongoing equity value creation at TMUS as it maintains 5G leadership and unlocks merger synergies," the company in a statement."